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Abstract
Human height is a complex trait with a high heritability. Mutations in the home-
obox gene SHOX cause SHOX deficiency, the most frequent monogenic cause of
short stature. SHOX deficiency has high penetrance. However, the clinical severity
of SHOX deficiency varies widely, ranging from short stature without dysmorphic
signs to mesomelic (disproportionate) skeletal dysplasia (Léri-Weill dyschondrosteo-
sis, LWD) and different independent studies have reported rare SHOX deficiency
individuals presenting with normal height and no dysmorphic signs. To shed light
on the factors that modify disease severity/penetrance, we studied a three-generation
family with five affected individuals presenting with LWD using whole genome link-
age and whole exome sequencing analyses. By combining the data obtained with
these two independent methods, we found that the variant allele p.Phe508Cys of the
retinoic acid catabolizing enzyme CYP26C1 co-segregated with the SHOX variant
allele p.Val161Ala in the 5 affected individuals, while the SHOX mutant alone was
also present in 3 asymptomatic family members.
Screening of a cohort of 68 LWD individuals led to the identification of two un-
related families with SHOX deficiency bearing also additional damaging CYP26C1
variants in the more severely affected family members. These results support a role
for CYP26C1 in influencing the course of disease in SHOX deficiency patients.
CYP26C1, similar to SHOX, is expressed in human primary chondrocytes and in
zebrafish pectoral fins. Luciferase assays performed to functionally characterize the
variants identified in SHOX and CYP26C1 demonstrated their damaging effects on
their activity: SHOX mutants were not able to transactivate the reporter gene ex-
pression, whereas damaging variants in CYP26C1 affect its catabolic activity leading
to increased levels of retinoic acid. High levels of retinoic acid significantly decreased
SHOX expression in human primary chondrocytes and zebrafish embryos. Analysis
of SHOX promoter unravelled an indirect effect of retinoic acid on SHOX expression.
Individual morpholino knockdown of either gene resulted in shortened pectoral fins
in zebrafish embryos, which was more pronounced in SHOX. Depletion of both genes
simultaneously, aggravated the fin phenotype. Together our findings demonstrate
that SHOX and CYP26C1 act in a common molecular pathway (retinoic acid signal-
ing) controlling limb growth and describe CYP26C1 as the first genetic modifier for
SHOX -associated disease.
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Zusammenfassung
Die Körpergröße des Menschen zählt zu den komplexen Merkmalen mit hoher Heri-
tabilität. Die häufigste monogenetische Ursache für Kleinwuchs sind Mutationen im
Homöoboxgen SHOX, die eine Defizienz des entsprechenden Genproduktes zur Folge
haben.
Eine SHOX Defizienz zeigt eine hohe Penetranz, wobei die klinischen Symptome stark
variieren und von Kleinwuchs ohne Anzeichen von Dysmorphien bis hin zu Klein-
wuchs mit mesomelischen (unproportionierten) Skelettfehlbildungen (Léri-Weill Dys-
chondrosteose, LWD) reichen. In seltenen Fällen treten SHOX Defizienzen auch ohne
phänotypische Auswirkungen, wie Kleinwuchs oder Skelettdysmorphien auf. Um Fak-
toren, die die Penetranz bzw. den Schweregrad von Kleinwuchs und auftretenden Dys-
morphien beeinflussen, zu identifizieren, wurde in dieser Arbeit eine Familie mit fünf
LWD-Individuen, verteilt über drei Generationen, mittels genomweiten Kopplungs-
analysen und Exomsequenzierungen untersucht. Auf diese Weise konnte eine hetero-
zygote Variante in dem Retinsäure katabolisierenden Enzym CYP26C1 identifiziert
werden, welche mit der SHOX Variante p.Val161Ala in allen fünf LWD-Patienten
ko-segregierte. Die entsprechende SHOX Variante war hingegen auch in drei nicht
betroffenen Familienmitgliedern vorhanden.
Untersuchungen in einer weiteren Kohorte bestehend aus 68 LWC-Patienten führten
zur Identifizierung zwei weiterer CYP26C1 Varianten in SHOX defizienten Patienten.
Letztgenannte stammen aus zwei nicht verwandten Familien und zeigten jeweils einen
schweren SHOX Defizienz Phänotyp. Die generierten Daten unterstützen die Hypo-
these, dass CYP26C1 die Ausprägung des Phänotyps bei Patienten mit eine SHOX
Defizienz beeinflusst.
CYP26C1 wird ebenso wie SHOX in humanen primären Chondrozyten bzw. in der
Brustflosse des Zebrafisches exprimiert. Zur funktionellen Charakterizierung der im
SHOX und CYP26C1 Gen gefundenen Varianten, wurden Luziferase Assays durch-
geführt. Diese Analysen belegten eine schädigende Wirkung aller Varianten auf die
jeweilige Proteinfunktion. Die SHOX Mutanten zeigten keine Transaktivierung des
Reporterkonstruktes, wohingegen die CYP26C1 Varianten die katabolische Aktivität
des Genproduktes reduzierten und so zu einer erhöhten Retinsäurekonzentration füh-
ren. Dieser Anstieg resultiert in einer signifikanten Reduktion der SHOX Expression
in humanen primären Chondrozyten sowie in Zebrafisch Embryonen.
Morpholino Knockdown Experimente für SHOX bzw. CYP26C1 führten in beiden
vii
Fällen zu einer Verkürzung der Brustflosse in den injizierten Zebrafisch Embryonen,
wobei für den SHOX spezifischen Genknockdown der zu beobachtende Phänotyp aus-
geprägter war. Der gleichzeitige Knockdown beider Gene im Modellsystem verstärkte
den Phänotyp.
Zusammengefasst zeigen die Ergebnisse, dass SHOX und CYP26C1 in den Retinsäu-
re Metabolismus involviert sind, die für die Extremitätenentwicklung verantwortlich
ist. CYP26C1 konnte somit als erster Modifier für SHOX assoziierte Erkrankungen
identifiziert werden.
viii
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1 Introduction
1.1 Height Matters
When we walk on the street very tall or very short people catch our attention at
once. Extraordinary tall or short people are registered in the Guinness Book of
World Records and invited to TV shows all around the world (Figure 1.1). Height
may have a strong
Figure 1.1: Variability in human height. Chandra
Dangi (on the left) and Sultan Kösen (on the right) are the
shortest and the tallest people in the world with an height of
54.6 and 251 cm, respectively (picture taken from the web).
Human height is variable and is determined both by geno-
type and environmental factors.
influence on individuals lives.
For example, it has been re-
ported that tall people have bet-
ter jobs, higher workplace suc-
cess and they usually emerge as
leaders1.
Height is an easy trait to mea-
sure. Stature is defined rela-
tive to the age, gender and ge-
netic background of the indi-
vidual. Tall stature and short
stature are defined as a standing
height above or below +2 or -
2 standard deviations (SDs), re-
spectively.
Height has a high heritability,
although many environmental
factors may affect it. So far,
many genes have been linked
to growth disorders, but many
more trait-loci may influence
height. Identifying the genetic
factors that influence height can
provide new insights into de-
velopment. Moreover, finding
the causes of growth disorders
may improve the management
of such conditions.
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1.1.1 Bone development
Height mostly, but not exclusively, depends on the longitudinal growth of the long
bones. Bone tissue formation, called ossification, takes place through two major devel-
opmental processes: intramembranous and endochondral ossification. In intramem-
branous ossification mesenchymal tissue directly converts into bone. Flat bones like
the skull typically develop via this process. In endochondral ossification mesenchymal
cells first differentiate into cartilage which is later replaced by bone. This process is
characteristic of long bones development.
Endochondral ossification
Endochondral ossification involves the aggregation of mesenchymal progenitors which
differentiate into cartilage tissue which is finally replaced by bone2. Cartilage tis-
sue formation, namely chondrogenesis, is a tightly regulated multi-step process which
involves molecular and morphogenetic changes3. Mesenchymal progenitors, once com-
mitted to chondrocytic fate, undergo through condensation, differentiation into pro-
liferative chondrocytes, withdraw from cell cycle to initiate hypertrophic differentia-
tion, programmed cell death, and ultimately substitution with bone tissue. During
hypertrophy, chondrocytes secrete extracellular matrix components which mediate
calcification. Perichondrocytes, cells which surround the cartilage tissue, differenti-
ate into osteoblasts and secrete bone matrix to form the periosteum. Blood vessels
start penetrating the periosteum and bring osteoclasts which degrade the cartilage.
Eventually, the chondro-osseous junction forms to divide the cartilage template into
the two epiphyses (Figure 1.2).
The elongation of bones occurs at the epiphysial plates or growth plates3. Each
growth plate is characterized by three zones: the resting zone, populated by round
resting chondrocytes which represent the pool of cells ready for later phases of prolif-
eration and differentiation; the proliferating zone, consisting of flattened proliferating
chondrocytes which organize in columns in the direction of longitudinal growth; hy-
pertrophic zone, composed of chondrocytes which undergo terminal differentiation by
withdrawing from the cell cycle and increasing their volumes (Figure 1.2 and Fig-
ure 1.3).
Many parameters contribute to the length of the long bones, including prolifer-
ation and extracellular matrix deposition. However, the great volume increase of
hypertrophic chondrocytes contribute the most to long bone lengthening and to the
different growth rates of the skeletal elements within an individual, individuals, and
species2. Hypertrophic chondrocytes undergo three different phases. In the first
phase, there is an initial expansion of the volume characterized by increase in dry
mass production and fluid uptake to maintain a normal dry mass density. In the
second phase, the enlargement is characterized by cell swelling resulting in a strong
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dilution of dry mass density. In the last phase, volume keeps increasing but dry mass
and amount of fluid proportionally increment. These processes are modulated to
achieve differential growth of individual elements within a species and of homologous
elements between species. For example, in the proximal tibia of mice hypertrophic
chondrocytes are large. By contrast, in the proximal radius cells are much smaller.
It has been shown that, while chondrocytes in the tibia go through the three hy-
pertrophic phases described above, those in the radius reach the second phase and
then stop increasing their volume by aborting the second phase and eliminating the
third one2. Finally, hypertrophic chondrocytes mineralize their extracellular matrix
and then undergo programmed cell death. The hypertrophic cartilage is invaded by
blood vessels, osteoclasts and osteoblast precursor cells that remodel the cartilage
and substitute it with bone tissues3.
Figure 1.2: Endochondral ossification. At the beginning of endochondral ossification, mes-
enchymal cells are committed to chondrocyte fate and start to condensate. Cells initiate differen-
tiation and start producing cartilage matrix. The chondrocytes in the cartilage template undergo
proliferation, exit the cycle, and become hypertrophic. Cells in the outer layer differentiate into
perichondral cells. Finally, during the process of bone formation and elongation, perichondral cells
adjacent to hypertrophic and apoptotic chondrocytes differentiate into osteoblasts which, together
with blood vessels, invade the cartilage template and substitute it with bone tissue. Figure adapted
from ref. 3.
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Regulators of endochondral ossification
Endochondral ossification is regulated by a complex network composed of several
genes. Different signalling pathways and transcription factors must be tightly reg-
ulated during this process and any disturbance may lead to skeletal disorders5.
Bone morphogenetic proteins (BMPs) and transforming growing factor β (TGFβ)
are growth factors belonging to the TGFb superfamily that are involved in the ini-
tiation of chondrogenesis. Once bound to specific membrane receptors, the signal is
transduced inside the cell to induce mesenchymal progenitors to start chondrocyte
differentiation (Figure 1.3)3.
Figure 1.3: Chondrocyte differentiation. Chondrocyte differentiation is regulated by a complex
network composed of several genes. Mesenchymal cells upon BMPs signalling become committed
to chondrocyte fate. Chondrocyte progenitors start differentiating under the drive of SOX9 and
other factors, and start depositing COL2A1 to form the cartilage matrix. Chondrocytes flatten,
proliferate, and organize columns in the longitudinal growth direction. Finally, SOX9 expression
starts decreasing and RUNX2 increasing to initiate hypertrophy. In this stage, chondrocytes enlarge
and start producing COL10A1 matrix. Hypertrophic cells eventually undergo programmed cell
death to be substituted by bone tissue. Figure adapted from ref. 3.
SRY-box 9 (SOX9) is a key transcription factor of chondrogenesis and maintenance
of chondrocyte identity. Heterozygous mutations in SOX9 in human have been linked
to campomelic dysplasia, a disorder characterized by disproportionate short stature
and bowing of the limbs. SOX9 is expressed in the mesenchymal progenitors and is
necessary for their differentiation into chondrocytes. It is expressed by proliferative
chondrocytes and during the hypertrophic stages, SOX9 synthesis is downregulated.
Indeed, whereas loss of Sox9 in prehypertrophic cells in mouse results in the conver-
sion to osteoblasts, overexpression of this gene delays ossification. Moreover, SOX9
inhibits terminal differentiation of hypertrophy. Among its target are SOX5 and
SOX6, genes involved in the ordered progression through the hypertrophy, and colla-
gen type II (COL2A1 ), a major components of the extracellular matrix of the early
stages of endochondral ossification (Figure 1.3)3;4.
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Another important transcriptional regulator of endochondral ossification is NK3
homeobox 3 (NKX3 )/bagpipe homeobox homolog 1 (BAPX1 ). This gene is expressed
in proliferative chondrocytes where it represses Runt-related transcription factor 2
(RUNX2 ) expression to prevent the initiation of chondrocyte hypertrophy5.
RUNX2 is an important regulator of hypertrophic differentiation. Its expression
starts at the beginning of hypertrophy and is maintained throughout it to promote this
differentiation process. RUNX2 activates the expression of hypertrophic chondrocyte
markers such as collagen10A1 (COL10A1) and indian hedgehog (IHH). Interestingly,
RUNX2 activity is inhibited by SOX9 through direct protein-protein interaction to
prevent cells to undergo hypertrophy4;5 (Figure 1.3) .
The final step of hypertrophic differentiation, which occurs at the boundary be-
tween cartilage and newly formed bone, calcium and phosphate trigger chondrocytes
to undergo programmed cell death (Figure 1.3). It is still not clear whether apopto-
sis occurs. Despite apoptotic factors like caspase-7 and BCLX appear to be involved
in the process, structural analysis of hypertrophic chondrocytes show distinguished
features from classic apoptosis, and autophagic vacuoles can be observed3.
Retinoic acid signaling in bone development
Many different signaling molecules contribute to the generation of the skeleton. Vi-
tamin A (retinol) and its metabolites are important signaling molecules throughout
embryonic development. Vitamin A is a lipid soluble molecule that must be ob-
tained from the diet. Retinoic acid (RA), obtained from retinol in two oxidation
steps, is the most active retinoid. RA has been shown to play important roles during
skeletogenesis. With regard to endochondral ossification, RA seems necessary during
chondroblast differentiation and chondrocyte hypertrophy. Excess of RA in condensed
cells prior to chondroblast differentiation induces downregulation of the expression of
chondroblast markers, such as Col2a1, and increased levels of condensed cells markers
that are normally downregulated upon differentiation4. RA has also been implicated
in later stages of skeletal development. In particular, excess of RA has been shown
to induce excess bone, while deficiency of this molecule results in enlarged zones of
cartilage with undermineralized matrix. It has also been proposed that RA has an
important role in chondrocyte maturation and replacement of hypertrophic cells by
bone4. Thus, RA has a dual role during endochondral ossification: it controls the
early differentiation from condensed cells to chondroblasts and, later on, it regulates
hypertrophic differentiation and replacement by bone. Eventually, RA localization,
timing and levels control size and shape of bones4.
RA exerts its activity mainly through the binding of its nuclear receptor subfamilies
retinoic acid receptors (RARs) and retinoic X recetpors (RXRs). These receptors bind
retinoic acid responsive elements (RAREs) in promoter regions of several genes and
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regulate transcription through interactions with coactivators and corepressors. RARs
and RXRs subfamilies contain three members each: α, β, γ. Within each subtype,
alternative splicing and/or promoter usage generate several isoforms. This diversity
may reflect different responses upon RA binding and thus gene regulation. During
skeletal development, RARs and RXRs are dynamically expressed and function as
important regulators of this process4. Interestingly, it has recently been shown that
retinoids can stimulate rapid, non-genomic signaling through extra-nuclear RARs.
Activation of these latter pathways triggers phosphorylation relays which regulate
downstream transcription events. Eventually, the retinoids pathway is even more
complicated by the potential to regulate RAR-related orphan receptors (RORα, β,
γ). RORs have also been implicated in ossification6.
It has been shown that both excess and deficiency of RA can have dramatic effects
on development. Therefore, it is of paramount importance to fine tune its levels over
time and space. RA levels depend on the activity of two groups of oxidizing enzymes:
the retinaldehyde dehydrogenases (RALDHs or ALDH1a) and the cytochrome P450
retinoic acid enzymes (CYP26s). First, retinol is oxidized by retinol dehydrogenases
(RDHs) to retinal. RALDHs (RALDH1, 2, and 3) then catalyze the oxidation of
retinaldehyde to RA, through an irreversible reaction. The cytochrome P450 26s
subfamily of enzymes (CYP26A1, B1, and C1) catalyze the oxidation of RA to 4-
oxo- and 4-hydroxy-RA, retinoids which are readily excreted and seem not to play a
role in development8 (Figure 1.4). During development, RALDHs and CYP26s are
differentially expressed in different tissues suggesting the importance of the spatio-
temporal fine tuning of RA levels.
Figure 1.4: Retinoic acid pathway. Retinol (ROL), vitamin A, is assumed through diet and
distributed to cells through the blood flow. Once in the cell, it may be stored or oxidized to retinal
(RAL) by RDHs in the cytosol. Retinal can be oxidized to RA by RALDHs. RA can go to the
nucleus to regulate gene expression or go to the microsomes, where it is catabolized by CYP26s to
4´-hydroxy-retinoic acid (4´OH-RA), which is readily excreted by cells.
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1.2 Short Stature and the SHOX gene
1.2.1 Short stature
Short stature affects approximately 3% of children worldwide and is diagnosed when
height is significantly below the average of the general population for that person´s
age and gender. More precisely, short stature is statistically defined as two standard
deviations (SD) below the mean population height for age, sex and ethnic group (less
than the third percentile) or, when evaluating shortness in relation to family back-
ground, more than two standard deviations below the mid-parental height7.
As discussed above, bone development is a highly complex process which involves
several factors. To date, several etiologies of short stature are known9;10 and many
genes underlying growth control have been identified e.g. COL2A1 11 and fibrob-
last growth factor receptor 3 (FGFR3 )12. The short stature homeobox-containing
(SHOX ) gene has been associated with a broad phenotypic spectrum ranging from
short stature without dysmorphic signs to profound dysplasia13–15. Its varied clinical
manifestations include idiopathic/isolated short stature, Lèri-Weill dyschondrosteosis
and Langer mesomelic dysplasia16 (Figure 1.5).
Idiopathic short stature
Idiopathic short stature (ISS)(OMIM 300582) is defined as a height below 2 SD in
regard to age, gender and ethnic group in the absence of specific causative disorders.
This term refers to individuals who do not present disorder of the growth hormone
(GH)/insulin like growth factor (IGF) axis. SHOX was associated to ISS in 199713.
Nowadays it has been estimated that SHOX deficiency accounts for 2 to 16 % of
ISS cases17. Children with ISS and SHOX deficiency are treated with recombinant
human growth hormone (rhGH).
Léri-Weill dyschondrosteosis
Léri-Weill dyschondrosteosis (LWD) (OMIM 127300) is a skeletal dysplasia charac-
terized by mesomelic short stature and Madelung deformity. LWD has a dominant
pattern of inheritance. Mesomelic short stature refers to a disproportionate shorten-
ing of the forearms and lower legs. Madelung deformity is a skeletal abnormality of
the distal radius resulting from premature closure of the distal radial growth plate
leading to an increased inclination of the radius, triangulation of the carpus and
dorsal displacement of the distal ulna. Madelung deformity is often associated with
decreased range of movement of the wrist and pain. Affected individuals may also
have other minor skeletal abnormalities e.g. micrognatia. The clinical manifestations
of LWD become more pronounced with age and are often more severe in females than
males. LWD was first associated to SHOX deficiency in 1998 by two different groups
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where they showed that mutations and deletions in the SHOX locus co-segregated
with the phenotype in several families14;15.
Mutations in SHOX regulatory regions have also been associated to LWD18. It
has been estimated that SHOX deficiency is responsible for 80-90% of LWD cases.
Hence, SHOX deficiency accounts for most LWD patients and it is thought
Figure 1.5: Clinical manifestations of SHOX -
deficiency. Heterozygous mutations or deletions in SHOX
allele lead to LWD a skeletal dysplasia characterizd by me-
somelic shortening of the limbs. Complete loss of functional
SHOX causes LMD, a more severe phenotype characterized
by extreme mesomelic short stature.
that those unresolved cases con-
tain mutations in uncharac-
terized SHOX regulatory re-
gions.
Treatment of LWD recommends
administration of recombinant
human growth hormone (hrGH).
This therapy has been shown to
improve the final adult height,
although data suggest that it
seems insufficient to prevent
the development of dispropor-
tionate growth and Madelung
deformity20. Madelung de-
formity is treated with ap-
proaches like cumbersome splint
or brace to keep straight the
wrist to alleviate discomfort
and, in severe cases, an inva-
sive surgical intervention is nec-
essary.
Langer mesomelic dysplasia
Langer mesomelic dysplasia
(OMIM 249700) is characterized
by severe limb aplasia or severe
hypoplasia of the ulna, and a
thickened and curved radius and tibia. Individuals present also Madelung deformity
and other minor skeletal abnormalities like micrognatia. Langer mesomelic dysplasia
(LMD) is more severe than LWD, supporting the hypothesis that it is an homozygous
state of dyschondrosteosis. Indeed, LMD is a more severe form of LWD caused by
homozygous loss of function of SHOX 14;15. Complete SHOX deficiency accounts for
100% cases of LMD. To date, there is no therapy for this condition.
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Turner syndrome
Turner syndrome clinical features include short stature, gonadal dysgenesis and skele-
tal abnormalities. Among the skeletal defects, patients can present cubitus valgus,
micrognathia, high-arched palate, webbed neck, Madelung deformity. The genetic
bases of Turner syndrome is partial or complete loss of one copy of the X chromo-
some in females. Individuals with Turner syndrome may also have cognitive deficits,
diabetes, heart and kidney abnormalities and autoimmune diseases22. This condi-
tion affects about 1:2000 to 1:5000 of girls and women21. SHOX deficiency has been
proposed as the cause for the skeletal abnormalities observed in Turner syndrome
patients23. Interestingly, Turner syndrome cases with trisomy of chromosome Xp,
as well as for other numerical sex chromosomes abnormalities (e.g. 47,XXX) have
been reported to be tall24;25. Tall stature in these individuals has been linked to
SHOX overdosage. SHOX overdosage leads to a delayed growth plate fusion and
consequently to longer limbs25. Turner syndrome associated short stature is treated
with hrGH to accelerate growth.
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1.3 SHOX gene, expression regulation and function
SHOX gene
The SHOX gene spans approximately 42 kb and localizes in the pseudoautosomal re-
gion (PAR1) shared between the X and Y chromosomes (chrX: 585079-607558; hg19).
It consists of 6 exons encoding for two different isoforms, SHOXa and SHOXb, which
differ in the 3‘-end encoded exon 616. However, RT-PCR analysis performed in fetal
and adult human tissues revealed 4 novel exons which have been proposed to con-
tribute to the fine-tuning of SHOX expression during development26.
SHOX is expressed in the human developing limbs already at five weeks post fer-
tilization as a band along the middle part of the limb. Analyses of human fetal and
pubertal growth plates revealed SHOX expression in resting, proliferative, and ter-
minally differentiated hypetrophic chondrocytes27;28. Interestingly, analysis of the
growth plates of LWD patients revealed a disordered distribution of the chondrocytes
instead of the typical columnar organization, clearly showing abnormal endochon-
dral ossification in SHOX deficiency individuals27. SHOX is also expressed in the
first and second pharyngeal arches, structures that develop into maxilla, mandible
and ear23. Noteworthy, patients with SHOX deficiency and Turner syndrome may
present a combination of skeletal defects in the anatomical structures where SHOX is
expressed: mesomelia, Madelung deformity, micrognatia, high-arched palate, low-set
ears.
SHOX expression regulation
SHOX expression is restricted during development. Several studies have identified
different mechanisms regulating SHOX expression16. One of the first investigations
identified two alternative promoters, P1 and P2, upstream of exon 1 and exon 2,
respectively. Activation of P1 or P2 generates two mRNA differing in the 5‘-UTR
(Figure 1.5). The authors demonstrated that P1 usage leads to the synthesis of
transcripts containing seven AUG codons in the 5‘-UTR which compete with SHOX
starting codon, resulting in reduced translation efficiency29.
Highly conserved enhancer regions have been found upstream and downstream of
the SHOX gene. Gene reporter experiments showed enhancer activity of these regions
in U2OS human cell line, chicken buds and zebrafish embryos31–33;40. Furthermore,
mutations and deletions of these enhancer sequences have been identified as cause of
many cases of short stature. However, the molecular mechanisms controlling these
regulatory sequences are not known yet. Studies in chick limb buds revealed the first
evidences of proximal and distal signals regulating Shox expression. In particular,
it has been shown that Fgf4 and Fgf8, Bmp4, and RA reduced Shox mRNA levels
(Figure 1.6)34.
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Figure 1.6: The SHOX gene and its expression regulation. SHOX localizes in PAR1
and is composed of 6 exons. Two promoters control SHOX expression, P1 and P2. P1 controls
the synthesis of longer 5´UTR transcripts carrying seven untranslated AUG codons which may
compete with the SHOX starting codon leading to low translation efficiency. The P2 product lacks
these elements resulting in high efficient translation of SHOX. SHOX expression is also regulated by
upstream and downstream conserved enhancers elements (CNEs). Moreover, experiments in chicken
identified Fgf4, Fgf8, Bmp4 and RA as signal molecules capable of inhibiting SHOX expression in
the limb buds. Finally, SHOX encodes for two isoforms differing in the C-terminal sequence, SHOXa
and SHOXb. SHOXb lacks the OAR domain and it may be unable to transactivate its targets, but
it may form heterodimers with SHOXa to regulate its transcriptional activity.
11
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SHOX function
SHOX gene encodes for a transcription factor belonging to the homeobox-containing
genes16. SHOXa and SHOXb isoforms are translated in proteins of 292 and 225
amino acids, respectively. Both isoforms contain the homeodomain, which con-
sists of 60 amino acids. This structure is composed of three α-helices which form
a helix-turn-helix motif and constitute the DNA-binding domain. Electromobility
shift assay (EMSA) analysis showed that SHOX binds to palindrome motifs 5‘-
TAAT(N)2-3ATTA-3‘, where N is the number of nucleotides separating the palin-
drome sequence. Missense mutations within the homeodomain have been reported in
individuals with ISS, LWD, and LMD.
SHOX exerts its DNA binding and transcriptional activity through the formation
of homo- and hetero-dimers through the homeodomain35. Studies identified brain
natriuretic peptide (BNP), aggrecan (ACAN ), FGFR3, and connective tissue growth
factor (CTGF ) as direct targets of SHOX36–39. These genes are expressed in limbs
and play a role in endochondral ossification, further supporting a role of SHOX in
bone formation and short stature.
The two SHOX protein isoforms differ in the C-terminal sequence. In this se-
quence the transactivation domain Otp Aristaless Rax (OAR) is present. SHOXb
lacks the OAR domain; therefore it has been suggested that it cannot perform tran-
scriptional activity alone. However, SHOXb may regulate SHOXa transcriptional
activity through the formation of heterodimers35.
Missense mutations found in SHOX deficiency individuals helped revealing other
important features of SHOX protein. Studies on LWD patients reported that sub-
stitution of A170 and R173, for example, affects the localization of SHOX protein.
These studies led to the identification of the non-canonical nuclear localization signal
in the peptide sequence AKCRK, which resides within the homeodomain40–42.
High expression of SHOX can be noted in the hypertrophic region, thus cells which
will soon undergo cell death to be substituted by bone tissue. It has been shown
that SHOX overexpression in U2OS cells and human primary chondrocytes induces
arrest in G2/M phases of the cell cycle, altered expression of cell cycle genes such
as p21Cip1, oxidative stress, and cell death28;44. Overexpression of SHOX bearing
mutations in the homeodomain does not lead to these events, indicating that they
are dependent on SHOX transcriptional activity28;43;44. However, direct evidence of
SHOX as regulator of genes involved in these pathways have not been reported yet.
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1.4 Aim of the project
A phenotype results from the interactions between genotype and environment. It has
always been of interest to understand how these relationships lead to the phenotypic
variability among individuals. Although many genes have been associated to disease
phenotypes, many clinical reports have shown that a phenotype might not occur as
often as the related genotype.
SHOX deficiency has a high penetrance. However, the clinical severity of SHOX de-
ficiency varies among individuals, even in family members with the same SHOX gene
mutation45;46. In rare cases, family members with the identical mutation present
with normal stature19;47;48. The aim of this study was to identify potential modifier
gene(s) as basis for the observed clinical variability in LWD individuals presenting
with mesomelia and Madelung deformity. This project started when we screened for
mutations in the SHOX gene in a large German family with LWD. Finding affected
and normal height individuals carrying the same SHOX damaging variant offered us
a rare opportunity to investigate the genetic origin of the observed clinical variabil-
ity. The primary goal of this project was therefore to perform genetic analyses for
candidate genetic modifier(s) identification. These analyses led to the retinoic acid-
metabolizing enzyme CYP26C1 as potential modifier gene. In the second part of this
thesis, functional analysis in human cells and zebrafish embryos were performed to
further corroborate the hypothesis of CYP26C1 as modifier gene for SHOX deficiency.
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2 Materials and Methods
2.1 Patients and controls
2.1.1 Family 1 clinical data
Family 1 comprised 17 German individuals with five affected members diagnosed
with Léri-Weill dyschondrosteosis. DNA was available from 14 individuals (I:1, I:2,
I:3, II:3, II:4, II:6, II:7, II:8, III:1, III:2, III:3, III:4, III:5, III:6). Four females (I:2, I:3,
II:7, III:2) presented a Madelung deformity (MD). In one affected male (II:3), the MD
was borderline. Three female individuals (II:4, II:8, and III:1) presented with short
stature, but no dysmorphic phenotype and no SHOX deficiency. The index patient
(III:2) was treated with growth hormone from the age of 8.9 years onwards. Age of
menarche was of 12 years. Further details on the clinical data are given in the Results
part and on Table 3.1.
2.1.2 Cohort of LWD patients with SHOX deficiency
The sample comprised 68 unrelated cases with LWD and proven SHOX deficiency;
it comprised 60 Europeans (28 Germans) and 9 Japanese. Two out of the 68 cases
carried damaging mutations in CYP26C1 and all the available family information
was retrieved (see below).
Family 2 comprised 4 French people with two affected children; parents were unaf-
fected. Patient II:2 presented LWD with mesomelia and Madelung deformity (avail-
able clinical data are given in Table 3.2). Patient II:1 presented with short stature
but did not show dysmorphic signs.
Patient 3 is a Japanese girl with mesomelia and Madelung deformity (available
clinical data are given in Table 3.2). The parents and the brother were reported
having normal stature and no dysmorphic signs.
2.1.3 Cohort of ISS and LWD patients with intact SHOX
The cohort of ISS individuals without SHOX deficiency (n = 234) comprised 96 Ger-
mans, 13 Belgians, 10 Americans, and 115 Japanese.
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The cohort of patients with LWD without SHOX deficiency (n = 22) is composed
of 17 Germans, 2 French, 1 Italian, 1 Dutch, 1 Swedish.
Family 4 comprised a German family with a son affected by ISS. Clinical data from
this individual nor of the parents could not be retrieved.
Family 5 comprised a Japanese family with the three ISS affected siblings (SD are
given in Figure 3.5). Both parents were reported with stature within the normal
range.
2.1.4 Controls
As controls we screened 140 Germans individuals with normal stature.
2.2 Whole Genome Linkage Analysis
Whole genome linkage analysis was performed by Dr. Gudrun Nuenrnberg (Center for
Molecular Medicine Cologne and Cologne Center for Genomics, Cologne, Germany).
2.3 Whole Exome Sequencing
Whole exome sequencing was performed by Dr. Tim Strom (Institute of Human Ge-
netics, Helmholtz Zentrum München, Neuherberg, Germany).
2.4 Reagents
Acetic Anhydride Sigma
All Trans Retinoic Acid (ATRA) Sigma-Aldrich
Adenosyn triphosphate (ATP) Sigma-Aldrich
BactoTM Tryptone BD
Biozym LE Agarose Biozym
Bromophenol Blue Sigma-Aldrich
CelLyticTM B Cell Lysis Reagent Sigma Aldrich
Citric acid Sigma-Aldrich
Diethylpirocarbonate (DEPC) Sigma-Aldrich
Dimethylformamide Sigma-Aldrich
DL-Dithiothreitol (DTT) Sigma-Aldrich
Ethylenediamine-tetracetic acid (EDTA) AppliChem
Ethanol Sigma-Aldrich
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Formamide Roth
Glucose Merck
Glycerol Sigma-Aldrich
Glycin Sigma-Aldrich
Heparin Sigma-Aldrich
Isopropyl-β-D-thiogalactopyranosid (IPTG) Serva
Isopropanol Sigma-Aldrich
KCl Merck
KH2PO4 Merck
Maleic Acid Roth
MgCl2 AppliChem
MgSO4 Merck
Na2HPO4 Merck
Na Citrate AppliChem
NaCl Sigma-Aldrich
Na Deoxycholate Sigma-Aldrich
NaOH Sigma-Aldrich
Igepal (NP-40) Chem-Cruz
Paraformaldehyde Roth
Polyacrilamide (37,5:1) Roth
Proteinase K Sigma-Aldrich
Sodium dodecyl solfate (SDS) Fluka
Torula yeast RNA Sigma-Aldrich
Triethanolamine Merck
Tris-HCl Roth
Triton X-100 Merck
Tween-20 Roth
X-Gal Serva
Yeast Extract BD
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2.5 Media and Supplements for Bacteriological Cultures
LB Medium 10 g Bacto-Tryptone
5 g Yeast Extract
10 g NaCl
Add ddH2O to 1 l and sterilize by autoclaving for 20 min
at 15 psi
LB Agar Plates Add 15 g Bact-Agar (BD) to 1 l LB Medium before autoclaving
(1.5% agar)
SOB Medium 20 g Bacto-Tryptone
5 g Yeast Extract
2 ml 5M NaCl
10 ml 1M MgCl2
0.5 ml 1M KCl
10 ml 1M MgSO4
Add dd H2O to 1 l and sterilize by autoclaving for 20 min
at 15 psi
SOC Medium Add 20 ml of filter-sterilized 20% (w/v) glucose stock solution to
1 l SOB medium
2x YT Medium 16 g Bacto-Tryptone
10 g Yeast Extract
2 g NaCl
Add dd H2O to 800 ml, adjust pH to 7.2, fill up to 1 l, and
sterilize by autoclaving for 20 min at 15 psi
Ampicillin (Roth) 100 mg/ml stock solution in 70% ethanol; used at 1:1000 dilution
Kanamycin (Roth) 30 mg/ml stock solution in ddH2O; filter-sterilized; used at
1:1000 dilution
Chloramphenicol 37.5 mg/ml stock ddH2O; filter-sterilized; used at 1:1000 or
(Roth) 1:3000 dilutions
Streptomycin 20 mg/ml stock ddH2O; filter-sterilized; used at 1:2000
(Biochrom)
X-Gal (Serva) 20 mg/ml stock solution in Dimethylformamide; used at 1:1000
dilution
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L-Arabinose 20% (w/v) arabinose stock solution in ddH2O; filter-sterilized;
(Sigma) used at 1:100 dilution
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2.6 Media and Supplements for Cell Cultures
Dulbecco’s Modified Eagle Medium (DMEM) (1x) High Glucose (Gibco)
Opti-MEM® Reduced Serum Medium (1x) with GlutaMAXTM (Gibco)
Dulbecco’s Phosphate Buffer Saline (DPBS) (Gibco)
Fetal Bovine Serum "Gold" (FBS) (PAA)
0.05% Trypsin-EDTA (1x) with Phenol Red (Gibco)
Non-Essential Amino Acid supplement (NEAA) (100x) (Gibco)
Penicillin-Streptamycin (Pen-Strep) (100x) (Gibco)
L-Glutamine (200 mM) (100x) (PAA)
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2.7 Bacterial Strains and Cell Lines
Bacterial strains
DH5α fhuA2 ∆(argF-lacZ)U169 phoA glnV44 Φ80 ∆(lacZ)M15
gyrA96 recA1 relA1 endA1 thi-1 hsdr17
NovaBlue GigaSinglesTM endA1 hsdR17(rK12− mK12+) supE44 thi-1 recA1 gyrA96 relA1
Competent Cells lacF[proA+ B+ lacIqZ∆M15::Tn10(TcR)](Novagen/Merck)
XL10-Gold Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44
Ultracompetent Cells thi-1 recA1 gyrA96 relA1 lac Hte[F′ proAB lacIqZ∆M15 Tn10
(Tetr) Amy Camr](Agilent)
PPY F endA1 recA1 galE15 galK16 nupG rpsL∆lacX74
Φ80lacZ∆M15 araD139∆(ara,leu)7697 mcrA
∆(mrr-hsdRMS-mrcBC) cynX::[araC pBAD-redα EM7-redβ
Tn5-gam]λ-
Cell lines
HEK293 Human Embryonic Kidney cell line; ATCC
U-2 OS Human Osteosarcoma cell line; ATCC
Primary cells
Human Primary Chondrocytes
2.8 Plasmids
pUC19 Invitrogen
pcDNA4/TO Invitrogen
pIRES2-EGFP Clonetech
pGL3promoter Promega
pRL-TK Promega
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pSTBlue-1 Novagen/Merck
2.9 Oligos
Primers for whole-exome sequencing Sanger sequencing validation
Primers were designed using Primer349.
Gene symbol Sequence (5’-3’)
EXO1 for TGTTCCCTGTTCTTTAGTTGCAGA
rev AGGATACTGCCAGCGTAGC
SYNDIG1 for TGACTTCCTTTTTCTTCTCCAACTC
rev ACAAAATAAATCCATGGGTAGGAAA
CYP26C1 for CCTCCAGCCGCTTCCATTAC
rev CGTTTGGCGAACATTTGTTGA
OPN4 for CGAGTGCCCTGCAAGGATAG
rev TCCCCAACCCTTTAGCCACT
LAMA1 for GACACACACGGCGAGATAGAGATT
rev CCCCTCTCTCCTGAGATGTTCAAT
TXNDC11 for CAGCCATTAGCTGCCAGAGT
rev GGGCCTTAGAAAACCAGGAG
BIRC7 for ACCTAAAGACAGTGCCAAGTGC
rev GAAACACTCAGCCAGCAGAGAC
USP19 for CCCGCTCCTTAGCCAACTCT
rev CCTGGTGTTTCAGGCCCTCTC
MACF1 for ACTTCTCCACCAAGCTGAGGTC
rev CACACTGTTTGTTCAGGGCTTC
NRAP for AGCCTTGGTTGTATCCGCTAACA
rev TCCAACTTCTTGTGATGGGTTGA
USP28 for TGAGCAGTACAGATTTTCCCCAAT
rev GACTTACAGGTGCCTTATCGCTTG
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CLTC for GGTCTGCTTCGCCTGTGTAGA
rev TTCTGCCCAAAGATGAGCTTG
FLYWCH1 for GGGACAAGGTGTATTGGACCTG
rev ACCTCTGGAGGCAAGAGTCAAG
PLB1 for CTGAAAAGCCCCAGAACTCCT
rev TGTCCAAGGGTGTGAGGATCT
FAT2 for CACCATGTCAGAGCCCTCAT
rev AGTCGTGATGCCAGAGCCTA
GPD1 for CCGTTGCCTTGGAGAAGTAG
rev GAGATGGCTAAGTGGGGTTG
ZNF267 for AGTGACTCCTCAGGTCTTACTGTGC
rev TTCTCTGCTATTGTGTAAGGCTTGA
PIP5K1B for GGAGCCAATTTGGGACATTA
rev AAACTTCCTTACCCGGCAGT
ACAN for GGTCACTGGTAAGAGAGGGACTCA
rev TTATGGACAAGGCTGTTTTTGTCA
OR1S2 for TTCCGTAGAACAGTAATGCAAT
rev CAACCAGGCTGAACATCAAA
LARP7 for TTCTGGCATAACCATTGGAA
rev AGGATCTCGAGTTTCCAGCA
SLC10A2 for ATCGGCCTCCATTACTTTTCAC
rev AATGAACCCTCTTGGCCACTTA
PCDH8 for GCCACTTCTAGGGAGCCATTG
rev CTCTATGGGCACGAGCACTTC
ZNF33B for TCACTTCCTAACAAAAGCCATCC
rev GCCAGAAGTCACAACTCACTCA
SUPV3L1 for AATTTGGAGGGCTTTCCATC
rev ACCAAAAATCCCCCAGTACC
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PIK3R6 for CAGCCTAATTACCCGCCTCT
rev CCCTGGAGCACTATTTCCAC
AOC2 for CATCCCTGAGGTCTCGGAAC
rev GATATAACCCGTGGCATGGAC
DOCK1 for TGGTCTCGATTCCACACAGC
rev TTGGGCACTACGGTCAGAAA
RIMBP2 for TGACGTGGCTGTAGTTGCTG
rev ATCGACGACATCGGAGAAGA
IGSF3 for TGACGTGGCTGTAGTTGCTG
rev ATCGACGACATCGGAGAAGA
TNKS1BP1 for CTATATGGGGCCATGCACTT
rev CTGGCTGAGTTGCCTTCCTG
KIF4A for AAGCCCGTGCACTCTCTTTA
rev ATGAAAGGCAAGACCACACC
LIG4 for TGATGTTCTCAGACCCTGCAAT
rev CTCCACCAAGCAGCATTTTATG
PCLO for GTGGTTGGCTTTACCATCTTGG
rev AGACTTCCCCAAAGAAGGATGC
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CYP26C1 Sanger sequencing primers
Primers were designed using Primer349.
Name Sequence (5’-3’)
CYP26C1 -Exon1 for CTTATAAATCTCGGGCTTTGC
rev GGGAAGAAGGGACCGTATTA
CYP26C1 -Exon2 for CCAGGGACAGGAAGTTGTG
rev CCGACGTATCTACGGTCCA
CYP26C1 -Exon3 for GAGAAAGGACCGGAACTGG
rev GAGCCTCGGAGGAAGGTC
CYP26C1 -Exon4 for TGAGAAGGTTTCTGGGTAAGTG
rev GTCATTACTGGAACCCAGGTCT
CYP26C1 -Exon5 for CGACTTCAAAACCGTACACA
rev TCTGAGGGCAAAAGAGGTG
CYP26C1 -Exon6 for GTGGTCAGGCTGATCTCCTC
rev TGGCGAACATTTGTTGAAAG
Primers to analyze SHOX p.Val161Ala mutation in the family study
Primers were designed using Primer349.
SHOX -Exon3 for GCCACGTTGCGCAAAACCTC
rev CCCGAGGACCAGGCGATG
CYP26C1 GS Junior Roche sequencing primers
Primers were designed using Primer349.
Barcodes were attached to each primer:
5’-ACACTGACGACATGGTTCTACA-specific forward primer-3’
5’-TACGGTAGCAGAGACTTGGTCT-specific reverse primer-3’
Name Sequence (5’-3’)
CYP26C1-Exon1a for CTTATAAATCTCGGGCTTTGC
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rev AACTAACCAGTGCAGCGTTT
CYP26C1-Exon1b for GAGCTGCCTGTCAGTGCT
rev GGGAAGAAGGGACCGTATTA
CYP26C1-Exon2a for CCAGGGACAGGAAGTTGTG
rev ACCGCACCTAGCAGTGTG
CYP26C1-Exon2b for ACAGTGTTCAAGACGCACCT
rev CCGACGTATCTACGGTCCA
CYP26C1-Exon3a for GAGAAAGGACCGGAACTGG
rev TGAGAAGAGGTTCTCCACGAG
CYP26C1-Exon3b for AGTCTACGACGCCTCCAAAG
rev GAGCCTCGGAGGAAGGTC
CYP26C1-Exon4a for TGAGAAGGTTTTCTGGGTAAGTG
rev CTTGCACTGTGAATGATTAGGTC
CYP26C1-Exon4b for ATCTTTCTTCTCTCCCTGAACATC
rev GTCATTACTGGAACCCAGGTCT
CYP26C1-Exon5a for CGACTTCAAAACCGTACACA
rev AGCTCCTCCCGAATCTTG
CYP26C1-Exon5b for GCTCGTCCTGCTGCTACTG
rev CAGCACCTCCTTGACCAC
CYP26C1-Exon5c for AAGATTCGGGAGGAGCTG
rev TCTGAGGGCAAAAGAGGTG
CYP26C1-Exon6a for GTGGTCAGGCTGATCTCCTC
rev GAACGGGATGTAATGGAAGC
CYP26C1-Exon6b for GATGTATAGCATCCGGGACAC
rev GTCAGAGGCATAGCCCATTC
CYP26C1-Exon6c for CTGCGGCTCTTTTTCCAC
rev TGGCGAACATTTGTTGAAAG
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Primers for CYP26C1 SLiCE cloning
Name Sequence (5’-3’)
pcDNA4-HisMaxC/CYP26C1exon1 (3’) TGGTACCGAGCTCGGATCC/
ATGTTCCCTTGGGGGCTGAG
CYP26C1exon1/CYP26C1exon2 (5’) AGCGCGAGCC/
CTGAACTAACCAGTGCAGCG
CYP26C1exon1/CYP26C1exon2 (3’) CACTGGTTAGTTCAG/
GGCTCGCGCTTCCACAGTTCTC
CYP26C1exon2/CYP26C1exon3 (5’) GCGCCAGGAC/
CTTGCGCCGCCGCCGG
CYP26C1exon2/CYP26C1exon3 (3’) GCGGCGCAAG/
GTCCTGGCGCGCGTGTTC
CYP26C1exon3/CYP26C1exon4 (5’) CCCGGATGCC/
CTTGCGTAGGCCACTGAAGGG
CYP26C1exon3/CYP26C1exon4 (3’) GGCCTACGCAAG/
GGCATCCGGGCAAGGGAC
CYP26C1exon4/CYP26C1exon5 (5’) CACAGCCGACTC/
CTTCAGCTCCTGCATGGAGGG
CYP26C1exon4/CYP26C1exon5 (3’) GCAGGAGCTGAAG/
GAGTCGGCTGTGGAGCTCC
CYP26C1exon5/CYP26C1exon6 (5’) GGATCTGGTAGCC/
GTCGAGCTCGAAGGTGCGC
CYP26C1exon5/CYP26C1exon6 (3’) CTTCGAGCTCGAC/
GGCTACCAGATCCCCAAGG
CYP26C1exon6/pcDNA4-HisMaxC (5’) TGGATATCTGCAGAATTC/
TCAGAGGCATAGCCCATTCC
26
Materials and Methods
Mutagenesis primers
Primers were designed according to the recommendations in the manual QuickChange
Lightning Site-directed mutagenesis Kit (Stratagene).
Name Sequence (5’-3’)
SHOX Val161Ala for CTCCGAGGCGCGCG[T>C]GCAGGTAGGAAC
rev GTTCCTACCTGC[A>G]CGCGCGCCTCGGAG
SHOX Leu132Val for AGCAGCTGAACGAG[C>G]TCGAGCGACTCTTC
rev GAAGAGTCGCTCGA[G>C]CTCGTTCAGCTGCT
SHOX Arg153Leu already present in our lab (Schneider K. U. et al., 2005)
CYP26C1 Phe508Cys for CGGCTCTTT[T>G]CCACCCCCTCACGCCTTCGG
rev GAGGGGGTGG[A>C]AAAAGAGCCGCAGCCCGTC
CYP26C1 Cys459Ala for GTGCGCGCAGC[TG>GC]CCTCGGCCAGGAGC/
TGGCGC
rev CTGGCCGAGG[CA>GC]GCTGCGCGCACCGCCG/
CCG
CYP26C1 Arg378His for CAAGGAGGTGCTGC[G>A]CCTCCTGCCGCC
rev GGCGGCAGGAGG[C>T]GCAGCACCTCCTTG
CYP26C1 Gln119Pro for CAGTGGCCGC[A>C]GAGTGCGCACATCC
rev GGATGTGCGCACTC[T>G]GCGGCCACTG
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RT-PCR primers
Primers were designed using Primer349.
Name Sequence (5’-3’)
SOX9 for GAAGGACCACCCGGATTACA
rev CGTTGACATCGAAGGTCTCG
SHOX for AAGTTTTGGAGAGCGGACTG
rev GCCTCTGTTTCAGCTTGGTC
CYP26C1 for GTTCCCTTCAGTGGCCTACG
rev ACAGCCGACTCCTTCAGCTC
qPCR primers
Primers were designed using Universal Probe Library Assay Design Center (Roche).
Species Name Sequence (5’-3’)
Human
HPRT for TGATAGATCCATTCCTATGACTGAGA
rev AAGACATTCTTTCCAGTTAAAGTTGAG
SDHA for TGGGAACAAGAGGGCATCTG
rev CCACCACTGCATCAAATTCATG
SHOX for TGTTCAAGGACCACGTAGACA
rev GCGCTTCTCTTTGCATTCAT
Zebrafish
β-actin for GCAATGAGCGTTTCCGTTGC
rev TGGATACCGCAAGATTCCATACCC
eef1α for TCTCTACCTACCCTCCTCTTGGTC
rev TTGGTCTTGGCAGCCTTCTGTG
shox for GGTCGCTCCTTACGTGAATATGGG
rev TGCAACTGAGCCTGAACCTGTTG
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Whole-mount in situ hybridization probes primers
Primers were designed using Primer349.
Name Sequence (5’-3’)
sox9 for AAAGCGGATCTGAAACGAGA
rev CCATCATGCACTGAACGAAC
col2a1 for CATCAACGGGCAGATTGAGG
rev CAGCACGACTTTATTTTGCGT
shox for CGAATCCACGTTGAGCAGA
rev TGAGTGTCACGGCCTTTTC
Morpholino sequences
Morpholino where purchased from Gene Tools
Name Target Sequence (5’-3’)
cyp26c1 MO exon3-intron3 junction AACTACGGTTATCCTCACCTTGCGC
shox MO1 exon2-intron2 junction CGCATGGAAGAATGGGAGCTTACCT
shox MO2 exon1-intron1 junction CGTGCAGAAGAAACTCACCGTCAGA
Morpholino efficacy test primers
Primers were designed using Primer349.
Name Sequence (5’-3’)
cyp26c1 MO test for TATAGGATCCTTTTGGGCAAACCTCTCATC
rev TATAGGATCCAGTAATCGCTGGCTTGCTGT
shox MO1 test for TATAGGATCCGAGTTTAGCGTGACAAGGGC
rev TATAGGATCCGGTGAGGATGGGAGTGTGTT
shox MO2 test for TATAGGATCCTGAGCAGATAAAAGATTCGCGTTA
rev TATAGGATCCGAAACTGCAACTGAGCCTGAACCT
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2.10 Antibodies
Primary antibodies
Target Organism Number Company
human CYP26C1 IgG rabbit SAB1300952 Sigma-Aldrich
Secondary antibodies
Target Organism Label Number Company
rabbit IgG donkey IRDye® 800CW 926-32213 LI-COR
2.11 Kits
DNA isolation and purification
MinEluteTM PCR Purification Kit Qiagen
MinEluteTM Reaction Cleanup Kit Qiagen
MinEluteTM Gel Extraction Kit Qiagen
QIAquick® Nucleotide Removal Kit Qiagen
GeneJET Plasmid Miniprep Kit Thermo Scientific
PureLinkTM HiPure Plasmid Midiprep Kit Invitrogen
PCR
Taq DNA Polymerase with ThermoPol® Buffer New England Byolabs
Paq5000 DNA Polymerase Agilent Technologies
HotStarTaq DNA Polymerase Qiagen
Phusion Hot Start II High Fidelity DNA Polymerase Thermo Scientific
Q5® High-Fidelity DNA Polymerase New England Biolabs
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DNA sequencing
ExoI Thermo Scientific
DYenamicTM ET Dye Terminator Premix GE-HealthCare
SephadexTM G-50 Fine DNA Grade GE-HealthCare
MultiScreen 96-well plates Millipore
Real time PCR
SensiFASTTM SYBR® Lo-ROX Kit Bioline
Site-directed mutagenesis
QuickChange® Lightining Site-Directed Mutagenesis Kit Stratagene
Cloning
FastDigestTM Restriction Enzymes Thermo Scientific
FastAP Thermosensitive Alkaline Phosphatase Thermo Scientific
T4 DNA Ligase Thermo Scientific
pSTBlue-1 AccepTorTM Vector Novagen
Mix & Go E.coli Transformation Kit and Buffer Set Zymo Research
Total RNA extraction
TRIzol® Ambion
cDNA synthesis
SuperScript® II First-Strand Synthesis System for RT-PCR Invitrogen
in vitro RNA synthesis
MEGAscript® T7 Kit Ambion
MEGAscript® SP6 Kit Ambion
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DIG RNA Labeling Mix Roche
Reagents for transfection of eukaryotic cells
Lipofectamine® 2000 Invitrogen
PEI Sigma
Protein assays
Bicinchoninic Acid Kit for Protein Determination Sigma
1x Protease-Inhibitor Mix G SERVA
Luciferase assay
Dual-Luciferase® Reporter Assay System Promega
Cignal RARE Reporter Assay Kit (LUC) Qiagen
Detection of in situ hybridization probes
Blocking Reagent Roche
Anti-Digoxigenin-AP Fab fragments Roche
BM Purple AP Substrate precipitating Roche
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2.12 DNA-based Methods
2.12.1 PCR
PCR were performed to amplify DNA fragments for subsequent sequencing, cloning, muta-
genesis and expression analysis. Amplification conditions were set according to the manufac-
turer’s manuals.
2.12.2 Real time PCR
Real time PCRs were performed using the SensiFASTTM SYBR® Lo-ROX Kit and run in
the 7500 Fast Real Time PCR System (Applied Biosystems).
Reaction mix were assembled as follows:
10 µl SensiFAST SYBR Lo-ROX Mix (2x)
0.8 µl Forward primer (10 µM)
0.8 µl Reverse primer (10 µM)
2 µl Template DNA
X µl (final volume 20 µl) DNAse-free water
2.12.3 DNA purification
PCR fragments or linearised vectors were purified using MinEluteTM PCR Purification, Re-
action Cleanup, and Gel Extraction Kits following the manufacturer’s manuals. Plasmid
DNAs were purified using GeneJET Plasmid Miniprep Kit or PureLinkTM HiPure Plasmid
Midiprep Kit from 5 ml or 100 ml overnight culture, respectively.
2.12.4 Cloning
Restriction digestion
Plasmids and PCR fragments were digested with FastDigest restriction enzymes according
to the recommendations.
Dephosphorylation
Digested vectors were dephosphorilated with FastAP Thermosensitive Alkaline Phosphatase
to prevent self ligation.
Ligation
Vectors and inserts were purified, mixed in a molar ratio 1:3, and ligated using T4 DNA
Ligase according to the manufacturer’s recommendations.
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psTBlue-1 cloning
RNA in situ probes were prepared from DNA template and cloned in pSTBlue-1 vector.
PCRs were performed with HotStarTaq DNA polimerase from cDNA prepared from 36 hours
post-fertilization zebrafish embryos. PCR fragments were gel-purified and then cloned in the
vector using the pSTBlue-1 AccepTorTM Vector according to manufacturer’s protocol.
Site-directed mutagenesis
Mutations were introduced in SHOX and CYP26C1 with the QuikChange Lightning Site-
Directed Mutagenesis Kit. Primer design and reactions were carried out following the man-
ufacturer’s manual.
SLiCE cloning
SLiCE (Seamless Ligation Cloning Extract) is a bacterial cell extract used to assemble mul-
tiple DNA fragments DNA molecules via single in vitro recombination reaction50. This
strategy requires short end homologies (≥15 bp) between fragments.
To prepare SLiCE extract:
- Streak PPY glycerol stock (kind gift obtained from Dr. Yongwei Zhang) on a LB agar
plate (10 µg/ml streptomycin and 12.5 µg/ml chloramphenicol);
- Incubate at 37◦C overnight;
- Pick up a single colony and grow into a 50 ml tube containing 25 ml 2x YT medium
with 10 µg/ml streptomycin;
- Incubate at 37◦C shaking 250 rpm overnight;
- Dilute cells to 0.03 OD600 in a 500 ml flask of 2x YT medium with 10 µg/ml strepto-
mycin;
- Incubate at 37◦C 250 rpm until the culture reaches 0.6 OD600;
- Induce expression by adding L-arabinose to a final concentration of 0.2%;
- Incubate for 4-6 hours at 37◦C 250 rpm;
- Transfer cells into two 50 ml centrifuge tubes and pellet at 5,000 x g for 20 minutes at
4◦C;
- Wash pellets with 50 ml ddH2O and repeat centrifugation step;
- Resuspend pellets in 300 µl CelLyticTM B Cell Lysis Reagent;
- Transfer cells into a low-binding 1.5 ml tube and incubate at room temperature for 10
minutes to allow lysis;
- Centrifuge lysates at 20,000 x g for 2 minutes at room temperature;
- Collect supernatant into a new 1.5 ml tube, mix with equal volume of 100% autoclaved
glycerol and dispense in low-binding PCR tubes;
- Store SLiCE extract at -80◦C
34
Materials and Methods
SLiCE cloning were performed as follows:
- Linearise vector by restriction digestion or PCR;
- Amplify inserts by PCR reaction with primers containing homologies (18-20 nt) to the
vector or the flanking fragments;
- Gel purify vector and inserts;
- Assemble SLiCE reaction as described below;
- Incubate at 37◦C for 1 hour and then place on ice;
- Transform into electro/chemo competent DH5α cell strain.
SLiCE reactions were assembled as follows:
X µl linearised vector (50-100 ng)
X µl assembly fragments (1:1 or 1:3 molar ratio vector:fragment)
1 µl 10x SLiCE buffer
1 µl 10x PPY SLiCE extract
X µl (final volume 10 µl) Nuclease-free water
SLiCE buffer (stored at -20◦C):
500 µl 1 M Tris-HCl pH 7.5
50 µl 2 M MgCl2
100 µl 100 mM ATP
10 µl 1 M DTT
440 µl Nuclease-free water
Transformation
Transformations in DH5α cells were performed as follows:
Electro-competent cells:
- Purify ligation reaction (or SLiCE reaction);
- Add DNA to 100 µl of thawed cells;
- Electroporate at 1,800 V and followed by adding 500 µl of pre-warmed SOC medium;
- Incubate cells for 60 minutes at 37◦C in a bench shaker at 300 rpm;
- Distribute 50-100 µl of bacteria on pre-warmed LB-agar plates with appropriate an-
tibiotic and grown overnight at 37◦C.
Chemo-competent cells:
- Purify ligation reaction (or SLiCE reaction);
- Add 1-2 µl of DNA to 100 µl of thawed cells;
- Incubate 5-10 minutes on ice and add 500 µl of pre-warmed SOC medium;
- Incubate cells for 60 minutes at 37◦C in a bench shaker at 300 rpm;
- Distribute 50-100 µl of bacteria on pre-warmed LB-agar plates with appropriate an-
tibiotic and grown overnight at 37◦C.
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Electro-competent cells preparation
- Streak cells on a LB-agar plate without antibiotics;
- Pick up one colony and let it grow in 50 ml LB-media without antibiotics shaking at
250 rpm at 37◦C overnight;
- Prepare 4x 2 ml flasks with 500 ml LB-media without antibiotics and 1x 2ml flask
with 400 ml LB-media without antibiotics and add 5 and 4 ml of overnight culture,
respectively;
- Let the cells grow shaking at 250 rpm until they reach 0.4 OD600 ;
- Transfer cells in pre-chilled (on ice) centrifuge tubes;
- Incubate on ice for 30 minutes;
- Centrifuge at 8,000 g at 4◦C for 15 minutes;
- Wash pellet with 200 ml of autoclaved ice-cold ddH2O;
- Repeat centrifugation step;
- Wash pellet with 100 ml of autoclaved ice-cold ddH2O;
- Repeat centrifugation step;
- Wash pellet with 40 ml autoclaved ice-cold ddH2O with 10% v/v autoclaved glycerol;
- Transfer cells to ice-cold 50 ml tubes;
- Repeat centrifugation step;
- Resuspend pellet with a 1:1 volume of autoclaved ice-cold ddH2O with 10% v/v auto-
claved glycerol;
- Aliquot 100 µl of cells into pre-chilled 1.5 ml tubes (-20◦C);
- Put tubes immediately in liquid nitrogen;
- Store at -80◦C.
Chemo-competent cells preparation
Chemocompetent cells were prepared with the Mix & Go E.coli Transformation Kit and
Buffer Set:
- Streak cells on a LB-agar plate without antibiotics;
- Pick up one colony and let it grow in 50 ml LB-media without antibiotics at 250 rpm
at 37◦C overnight;
- Grow 0.5 ml of overnight culture in 50 ml of ZymoBrothTM (Zymo Research) medium
until they reach 0.4 OD600;
- Prepare fresh Wash and Competent Buffer by diluting each of them 1:1 with Dilution
Buffer, keep on ice;
- Transfer cells in 50 ml ice-cold tubes;
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- Incubate on ice for 10 minutes;
- Centrifuge at 2,500 g at 4◦C for 10 minutes;
- Wash pellet on ice in 5 ml ice-cold Wash Buffer;
- Repeat centrifugation step;
- Remove as much as possible of Wash Buffer and gently resuspend the cells in 5ml
ice-cold Competent Buffer;
- Aliquot on dry-ice 0.05-0.1 ml of cells into pre-chilled (-20◦C) 1.5 ml tubes;
- Store at -80◦C.
Transformation efficiency calculation
Transformation efficiency of prepared electro- or chemocompetent cells was calculated as
follows.
- Transform 1 µl (10 pg) of control pUC19 DNA into 50 µl cells;
- Grow by adding 500 µl of SOC medium;
- Dilute 50 µl in 1 ml;
- Plate 50 µl of cells;
- Count colonies;
- Calculate efficiency with the formula:
Transformation Efficiency = n◦ colonies x µg DNA x dilution factor
2.12.5 Agarose gel electrophoresis
Agarose gels 1-2 % in 1x TAE buffer were run at 80-150 V to verify or gel purify DNA
fragments. Depending on the size of the bands to analyse, the markers GeneRuler 100 bp
Plus DNA Ladder (Thermo Scientific) or GeneRuler 1 kb DNA Ladder (Thermo Scientific)
were used.
TAE buffer 50x (stored at room temperature):
242 g Tris-HCl
100 ml 0.5 mM EDTA
57.1 ml glacial artic acetic acid
Adjust to pH 8.3
X l (final volume 1 l) ddH2O
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2.12.6 DNA sequencing
After PCR amplicons were treated with ExoI and FastAP to degrade single strand DNA
molecules and dephosphorylate free dNTPs:
0.25 µl ExoI (20 U/µl)
0.50 µl FastAP (1 U/µl)
0.75 µl PCR product
2.5 µl Nuclease-free water
After treatment PCR products were prepared for Sanger sequencing as follows:
2 µl PCR product
0.25 µl Primer Forward or Reverse (20 µM)
1 µl DYenamicTM ET Dye Terminator Premix
1.75 µl Nuclease-free water
Cycling conditions:
30x 95
◦C 20 seconds
60◦C 2 minutes
Finally, 15 µl nuclease-free water were added to each sample. Reactions were then purified
with pre-hydrated SephadexTM G-50 Fine DNA Grade in MultiScreen 96-well plates. Briefly,
the plates were filled with sephadex and hydrated with 300 µl of ddH2O overnight (3-4 hours
are sufficient). Plates were then spun down at 3500 x g for 5 minutes and washed with 100
µl of ddH2O. Sequencing reactions were finally loaded on the plate, centrifuged at 3500 x g
for 5 minutes and run on the MegaBACETM System (GE Healthcare). Data were analysed
using the MegaBACE Sequence Analyzer (v3.0).
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2.13 RNA-based Methods
2.13.1 RNA isolation from human cells
Total RNA was isolated from cells as follows.
- Remove growth media from cells;
- Wash cells once or twice with PBS;
- Add a volume of TRIzol® adequate to cover the surface of the well;
- Pipette up-down several times to resuspend the cells;
- Transfer the volume into RNAse-free tubes and incubate 5 minutes at room tempera-
ture to allow cell lysis;
- Add chlorophorm 0.2 ml per ml of TRIzol used and shake vigorously the tubes for 15
seconds;
- Incubate the tubes for 2-3 minutes at room temperature;
- Centrifuge at 12,000 x g for 15 minutes at 4◦C;
- Transfer the aqueous phase to a new RNAse-free tube;
- Add 100% isopropanol 0.5 ml per 1 ml of TRIzol;
- Incubate at room temperature for 10 minutes;
- Centrifuge at 12,000 x g for 10 minutes at 4◦C;
- Remove the supernatant from the tube, leaving the RNA pellet;
- Wash the pellet with 1 ml of 75% ethanol per 1 ml of TRIzol and briefly vortex;
- Centrifuge at 7,500 x g for 5 minutes at 4◦C;
- Remove supernatant and air-dry pellet;
- Add 15-50 µl of RNAse-free water and up-down pipette the solution to resuspend the
pellet;
- Incubate in a heat block at 55-60◦C for 10-15 minutes;
- Proceed to downstream applications or store at -80◦C.
2.13.2 Reverse-transcription PCR
RT-PCR was performed using the SuperScriptTM II Kit according to the manual.
1 µg total RNA was reverse transcribed as follows:
- Prepare:
X µl total RNA (1 µg)
1 µl dNTPs (10 µM)
1 µl Random examers (50 ng/µl)
X µl (final volume 10 µl) Nuclease-free water
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- Incubate reactions for 5 minutes at 65◦C and cool down on ice for more than 1 minute;
- Add:
2 µl RT-buffer (10x)
4 µl MgCl2 (25 mM)
2 µl DTT (0.1 M)
1 µl RNaseOUTTM inhibitor (40 U/µl)
- Mix gently and brief centrifuge;
- Incubate at 25◦C for 2 minutes;
- Add 1 µl of SuperScriptTM II RT (200 U/µl) enzyme and mix by pipetting gently up
and down;
- Incubate at 25◦C for 10 minutes;
- Incubate at 42◦C for 90 minutes;
- Incubate at 70◦C for 15 minutes;
- Add 1 µl RNAse H (2 U/µl) and incubate at 37◦C for 20 minutes;
- Add 40 µl of Nuclease-free water.
2.13.3 DIG-RNA probes synthesis
DIG-RNA synthesis of probes for whole-mount in situ hybridization were prepared using the
DIG RNA Labeling mix with the MEGAscript® SP6/T7 Transcription Kit as follows:
- Linearise the pSTBlue-1 vector containing the probe sequence with the appropriate
restriction enzyme;
- Gel-purify the linearised vector;
- Prepare:
X µl corresponding to 1 µg of linearised vector
2 µl Transcription Buffer with DTT (10x)
2 µl DIG RNA Labeling Mix (10x)
1 µl RNaseOUTTM inhibitor (40 U/µl)
1 µl SP6 (20 U/µl) or T7 (15 U/µl) RNA polymerase
X µl (final volume 20 µl) Nuclease-free water
- Incubate at 37◦C for 2 hours;
- Add 1 µl of TURBO DNase (2 U/µl);
- Incubate at 37◦C for 15 minutes;
- Add 1 µl of EDTA (0.5 M);
- Add 1.3 µl LiCl (8 M);
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- Add 70 µl cold absolute Ethanol (-20◦C) and incubate at room temperature for 1 hour;
- Centrifuge at maximum speed with bench microcentrifuge at 4◦C for 30 minutes;
- Discard the surnatant and wash with 1 ml of cold 75% Ethanol-DEPC water (-20◦C);
- Centrifuge at maximum speed with bench microcentrifuge at 4◦C for 10 minutes;
- Let the pellet air-dry at room temperature for 10-15 minutes;
- Resuspend the pellet with 20 µl of 2x SSCT-50% Formamide;
- Check the probe on an agarose gel and store at -20◦C.
SSC 20x:
87.65 g NaCl
44.1 g NaCitrate
Bring volume to 350 ml with DEPC water
Adjust pH to 4.5/5.0 with Citric acid (1 M)
Bring volume to 500 ml
Autoclave
2x SSCT-50% Formamide:
5 ml 2x SSCT
5 ml 50% Formamide
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2.14 Protein-based Methods
2.14.1 Protein isolation
Proteins were isolated from cells grown in 6-well plates as follows:
- Place cell plates on ice and wash twice with PBS;
- Add 300 µl of RIPA or Tris-Triton buffer supplemented with 1x Protease-Inhibitor Mix
G and use the cell scraper to harvest them;
- Transfer the cells in a 1.5 ml tube and incubate on ice for 10 minutes to allow lysis;
- Centrifuge at maximum speed with a bench microcentrifuge at 4◦C for 30 minutes;
- Transfer the supernatant containing the protein lysate in a new 1.5 ml tube and store
at -80◦C.
RIPA buffer:
25 mM Tris-HCl pH 7.6
150 mM NaCl
1% NP-40
1% sodium deoxycholate
0.1 % SDS
Tris-Triton buffer:
10 mM Tris-HCl pH 7.4
100 mM NaCl
1% Triton X-100
10% Glycerol
1% sodium deoxycholate
0.1 % SDS
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2.14.2 Microsome enrichment
Microsomal preparations were obtained following the instruction of a protocol which can be
found at www.biomol.de/infos-general.html?id=246. The protocol works as follows:
- Place cell plates on ice and wash 3 times with 2 ml of resuspension solution;
- Resuspend the cells with a cell scraper in 1.5 ml of resuspension solution supplemented
with 1x Protease-Inhibitor Mix G;
- Centrifuge at 360 g with a bench microcentrifuge at 4◦C for 2 minutes;
- Resuspend pellet with 1 ml of 100 mM potassium phosphate buffer pH 7.4 containing
10 mM EDTA;
- Sonicate the cell suspension for 20 x 1 second to lyse the cells;
- Centrifuge cell lysate at 10,700 g at 4◦C for 1 hour;
- Homogenize the pellet in 100-150 µl 50 nM potassium phosphate buffer pH 7.4 con-
taining 0.1 mM EDTA and 10% glycerol;
- Store at -80◦C.
Resuspension buffer:
8 mM Na2HPO4
1.5 mM KH2PO4
2.7 mM KCl
2.14.3 Determination of protein concentration
Protein concentration in cell lysates or microsome-enriched lysates was measured with the
BCA assay according to manufacturer’s protocol.
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2.14.4 Western blot
Protein expression was analysed by blotting the cell lysates as follows:
SDS-PAGE:
- Mix 20-30 µg of protein lysate with SDS sample buffer;
- Heat up for 3-5 minutes at 95◦C in water bath;
- Load samples in 10% polyacrilamide gels;
- Run samples at 130 V, 35 mA for 2 hours in NuPAGE® Electrophoresis System.
Sample buffer (6x):
0.225 mM Tris-HCl
50% Glycerol
5% SDS
0.05% Bromophenol Blue
0.25 mM DTT
Running buffer (5x):
0.25 M Tris-HCl
2.5 M Glycin
1% SDS
Blotting:
- Activate the PDVF membrane (Immobilon-FL Membrane, Millipore) in methanol;
- Assemble the "blotting sandwich";
- Run at 25 V, 125 mA for 90 minutes at room temperature in NuPAGE® XCell Blotting
devices;
- Wash the PDVF membrane in TBS for 5 minutes;
- Incubate in TBS + Odyssey Blocking Solution (LI-COR) 1:1 for 1 hour at room tem-
perature;
- Wash in TBS-T for 5 minutes;
- Incubate in TBS-T + Odyssey Blocking Solution 1:1 with the primary antibody (anti-
CYP26C1 was diluted 1:100) overnight at 4◦C on an orbital rotator;
- Wash 3 times with TBS-T for 5 minutes;
- Incubate in TBS-T + Odyssey Blocking Solution 1:1 with the secondary antibody
(diluted 1:8000) for 1 hour at room temperature light protected on an orbital rotator;
- Wash 3 times with TBS-T for 5 minutes light protected;
- Proceed with Odyssey Infrared Imaging System (LI-COR).
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Transfer buffer (10x):
0.25 M Tris-HCl pH 8.3
1.92 M Glycin
TBS (10x):
0.5 M Tris-HCl pH 7.5
1.75 M NaCl
TBS-T:
TBS 1x with 0.1% Tween20
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2.15 Cell-based Methods
2.15.1 Cultivation of eukaryotic cell lines
Human primary chondrocytes (obtained as previously described in Marchini et al., 200428)
U2OS (ATCC) and HEK293 (ATCC) were maintained in DMEM medium supplemented
with 10% FBS, 100 U/ml Pen-Strep and 2 mM L-Glutamine in a humidified atmosphere
with 5% CO2 at 37◦C. For HEK293 and U2OS cells every two-three days growth medium
was removed, cells were washed with PBS and trypsinized with 0.05% Trypsin-EDTA for
2-5 minutes at 37◦C. Trypsinization was stopped by adding fresh growth medium and cells
diluted 1:10.
2.15.2 Cryo-conservation
Cells were cryo-conserved in liquid nitrogen tanks. Briefly, trypsinized cells were spun down
and resuspended in FBS containing 5-10% DMSO. Aliquots of 1.5 ml were distributed in
cryo vials and gradually frozen at -80◦C in styrofoam boxes. After 24 hours, aliquots were
transferred into liquid nitrogen tanks.
2.15.3 Transfection
Lipofectamine 2000 transfection of U2OS cells
U2OS cells were transfected with Lipofectamine® 2000 according to manufacturer’s manuals.
- Add DNA and Lipofectamine into two separate tubes containing Opti-MEM® Reduced
Serum Medium (1x) with GlutaMAXTM;
- Incubate Lipofectamine for 5 minutes;
- Mix the DNA tube with the Lipofectamine tube;
- Incubate at room temperature for 20 minutes;
- Add dropwise the mix directly to the cells;
- Change the media after 3-4 hours of transfection;
- Allow transfection for 24 hours.
Lipofectamine 2000 transfection for SHOX luciferase assays
To test SHOX mutants, luciferase experiments were performed with the FGFR3 promoter,
a known SHOX target. SHOX wild type or mutants were cloned in the expression vector
pcDNA4/TO. FGFR3 promoter -3430/+464 was cloned in pGL3basic38. As control reporter
vector for transfection normalization pRL-TK was used. Transfections were performed in
U2OS cells with Lipofectamine 2000 as described above. Experiments were performed in
24-well plates (1 x 105 cells per well), each condition in triplicate.
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Reaction mix per well:
300 ng pcDNA4/TO empty vector, SHOX wild type or SHOX mutants
300 ng pGL3-FGFR3(-3430/+464)
150 ng TK-Renilla
2 µl Lipofectamine 2000
2 x 50 µl Opti-MEM
Transfection was allowed for 24 hours prior to Luciferase reporter assay was performed.
Lipofectamine 2000 transfection for CYP26C1 luciferase assays
To test CYP26C1 mutants the Cignal RARE Reporter Assay Kit (SABiosciences) was used.
The kit provides Firefly luciferase as gene reporter under the control of retinoic acid responsive
elements (RARE). Renilla luciferase was provided by the kit and was used for transfection
normalization. CYP26C1 wild type or mutants were cloned in the expression vector pIRES2-
EGFP (gently provided by Prof. Dr. Thomas Boettger). Transfections were performed in
U2OS cells with Lipofectamine 2000 as described above. Experiments were performed in
96-well plates (1 x 104 cells per well), each condition in triplicate.
Reaction mix per well:
100 ng pIRES2-EGFP empty vector, CYP26C1 wild type or CYP26C1 mutants
100 ng Cignal RARE System Kit
0.5 µl Lipofectamine 2000
2 x 25 µl Opti-MEM
Transfection was allowed for 24 hours. Cells were then treated with mock control or 250 nM
ATRA. After 24 hours treatment cells were prepared for Luciferase reporter assay.
Lipofectamine 2000 transfection for SHOX promoter luciferase assays
To test whether RA directly regulates SHOX P2 promoter and CNE3 where cloned in
pGL3basic firefly luciferase reporter gene as previously described33. rTK-RL was used for
transfection normalization. Experiments were performed in 24-well plates (1 x 105 cells per
well), each condition in triplicate.
Reaction mix per well:
500 ng pGL3-empty vector, or CNE3-SHOX P2 wild type promoter or mutant promoter
50 ng TK-Renilla
1.5 µl Lipofectamine 2000
2 x 50 µl Opti-MEM
Transfection was allowed for 24 hours. Cells were then treated with mock control or 250 nM
ATRA. After 24 hours treatment cells were prepared for Luciferase reporter assay.
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Luciferase assay
Luciferase reporter assays were performed with the Dual-Luciferase® Reporter Assay System
(Promega) according to the manufacturer’s protocol. Briefly, cells were washed twice with
PBS and lysed with 60 µl (24-well plate format) or 20 µl (96-well plate format) of Passive
Lysis Buffer per well. Cells were incubated in lysis buffer for 15 minutes at room temperature.
Lysis was further supported by freezing at -80◦C and thawing before analysis. Cell lysates
were scraped with pipette tip and aliquoted in 96-well polypropylene flat bottom white plates
(Greiner Bio-one). Analysis were performed in the Berthold Centro LB 960 luminometer.
2.15.4 Treatment of human primary chondrocytes with ATRA
Human primary chondrocytes were treated with ATRA to test its effect on SHOX expression.
Briefly, cells were cultivated in 6-well plates. Once achieved full confluency cells were treated
with 10-100 nM ATRA for 6 hours. Finally, total RNA was extracted with TRIzol.
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2.16 Zebrafish-based Methods
Morpholino injection in zebrafish embryos were performed by Lonny Jürgensen and Prof.
Dr. David Hassel (Department of Internal Medicine III - Cardiology, University Hospital
Heidelberg, Heidelberg, Germany). ATRA treatment, RNA isolation, cDNA synthesis and
luciferase assays were performed by me and Lonny Jürgensen.
The shox and cyp26c1 morpholinos were obtained from Gene Tools. The standard control
morpholino (Gene Tools) was used as control.
MO efficiency test was performed by PCR on the provided cDNA. Amplicons were gel-
extracted and cloned in pUC19. Finally, single clones were Sanger sequenced.
2.16.1 Whole-mount in situ hybridization
Whole-mount in situ hybridization experiments were performed as described previously51.
Fixation:
- Fix embryos with 4% PFA in PBS for 1-4 hours at room temperature or 4◦C overnight;
- Wash embryos with PBST DEPC water for 5 minutes at room temperature;
- Repeat washing step;
- Take embryos through a methanol row of 10%-30%-50%-70%-100%-100%, rocking for
5 minutes at room temperature each step of the row;
- Embryos can be stored at -20◦C for at least 6 months.
4% PFA in PBS:
100 ml DEPC water
8 g paraformaldehyde
200 µl NaOH (10 N)
PBST DEPC:
100 ml PBS-DEPC (10x)
900 ml DEPC H2O
1 ml Tween-20
Proteinase K digestion:
- Take embryos through a reverse methanol row 100%-70%-50%-30%-10%-PBST DEPC-
PBST DEPC, rocking for 5 minutes at room temperature each step of the row;
- Place a metal heat block in the oven at 65◦C;
- Digest with 10 µg/ml of proteinase K in PBST DEPC at room temperature according
to the following guidelines for embryos hours post-fertilization (hpf):
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<24 hpf 3-5 minutes
24 hpf 8-10 minutes
48 hpf 18-20 minutes
75 hpf 26-30 minutes
- Rinse quickly in PBST DEPC;
- Wash in PBST DEPC for 5 minutes at room temperature;
- Fix in 4% PFA in PBS DEPC water for 20 minutes at room temperature;
- Rinse quickly in PBST DEPC water;
- Wash in PBST DEPC water for 5 minutes at room temperature.
Acetic anhydride treatment:
- Replace PBST DEPC water with DEPC water;
- Replace quickly DEPC water with a fresh mixture of acetic anhydride (2.5 µl/ml in
0.1 M triethanolamine pH 7.0 DEPC);
- Incubate for 1 hour rocking at room temperature;
- Place an aliquot of HYB- in the 65◦C oven;
- Wash in PBST DEPC for 10 minutes at room temperature;
- Repeat washing step.
Acetic anhydride mixture:
2.5 µl Acetic Anhydride
1 ml 0.1 M Triethanolamine in DEPC water
SSC 20x:
87.65 g NaCl
44.1 g NaCitrate
Bring volume to 350 ml with DEPC water
Adjust pH to 4.5/5.0 with Citric acid (1 M)
Bring volume to 500 ml
Autoclave
HYB- (store at -20◦C):
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50% ultrapure deionized Formamide
5x SSC (20x)
0.1% Tween-20
Pre-hybridization:
- Place embryos in 0.5 ml screw-top tubes with 500 µl of prewarmed HYB-;
- Incubate at 65◦C for 5 minutes;
- Place HYB+ in the 65◦C oven;
- Replace HYB- with HYB+;
- Incubate 1-48 hours, usually 3-4 hours are sufficient.
HYB+ (store at -20◦C):
HYB-
5 mg/ml torula yeast RNA
50 µg/ml heparin
Hybridization:
- Warm up more HYB+ at 65◦C;
- Add the probe (30-50 ng per sample) to 500 µl of pre-warmed HYB+;
- Incubate the mixture for 10 minutes before adding it to the embryos;
- Add pre-warmed mixture to the embryos (be aware of keeping the embryos on the
metal heat block to keep them warm);
- Incubate overnight at 65◦C.
Washing:
- Wash embryos with prewarmed 50%/2x SSCT at 65◦C for 30 minutes (perform the
washing steps on the metal heat block);
- Repeat washing step;
- Wash with pre-warmed 2x SSCT at 65◦C for 15 minutes;
- Incubate with RNAse A (10 µg/ml) in pre-warmed 2x SSC at 37◦C for 15-30 minutes;
- Wash with pre-warmed 2x SSCT at 37◦C;
- Wash with pre-warmed 0.2x SSCT at 65◦C for 30 minutes;
- Repeat washing step;
- Rinse with 0.2x SSCT at room temperature;
- Wash with 0.2x SSCT at room temperature for 5 minutes.
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2x SSCT:
5 ml 20x SSC
50 µl Tween-20
45 ml DEPC water
50% Formamide/2x SSCT:
5 ml 2x SSCT
5 ml 50% Formamide
Detection:
- Transfer embryos to a 24-well plate;
- Replace 0.2x SSCT with 2% Blocking Reagent (in MAB solution);
- Incubate at room temperature for 1-5 hours and rotate on an orbital shaker;
- Dilute 1:3000 the Anti-Digoxigenin-AP Fab fragments in 2% Blocking Reagent (in
MAB solution);
- Replace Blocking Reagent with the antibody solution;
- Incubate at 4◦C overnight on an orbital shaker;
- Wash embryos in 2% Blocking Reagent (in MAB solution) at room temperature for 25
minutes;
- Wash embryos with MAB solution at room temperature for 25 minutes;
- Repeat washing step twice;
- Bring the BM Purple AP Substrate to room temperature;
- Wash with Staining Buffer at room temperature for 5 minutes;
- Repeat washing step twice;
- Remove as much as possible the Staining Buffer;
- Add 500 µl of BM Purple AP Substrate;
- Stain at room temperature light protected checking every 30 minutes. If the desired
expression is not seen, one can leave the embryos at 4◦C overnight;
- Wash with PBST at room temperature for 10 minutes;
- Repeat washing step;
- Fix in 4% PFA-PBS at room temperature for 1 hour;
- Wash with PBST at room temperature for 5 minutes;
- Replace PBST with 100% glycerol;
- Store at 4◦C until ready to take photographs;
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MAB solution pH 7.5 (sterilize by filtering):
100 mM Maleic Acid
150 mM NaCl
X volume DEPC water
Staining buffer (prepare fresh):
50 mM MgCl2
100 mM NaCl
0.1 % Tween-20
1 mM Levamisol
100 mM Tris-HCl pH 9.5 (add last)
X ml autoclaved ddH2O
Photography
Embryos were placed on microscope slides. Images were taken with the microscope SZX16,
cellD Imaging Software (Olympus).
2.16.2 Pectoral fins area measurements
Pectoral fins area was measured with Fiji ImageJ52.
2.16.3 Luciferase assays
Luciferase experiments in zebrafish were performed injecting one-cell stage embryos with 1-2
nl of a 25 nM stock of Cignal RARE Reporter System plasmids and 1-2ng of control MO or
cyp26c1 MO. After 24 hr injection embryos were separated in groups of 20-30, lysed in 50
µl of Passive Lysis Buffer and assayed with the Dual Luciferase® Assay System as described
above. Each experiment was performed in triplicate and repeated three times.
2.16.4 ATRA treatments
Treatments of zebrafish embryos with RA were performed as follows: wild type embryos
were left developing for 24 hours. At 24 hpf, embryos were separated in groups of 10-15 and
treated with mock control, 50 or 100 nM ATRA for 6 hours. Finally, RNA was extracted
and used for shox expression analysis as described above.
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2.17 Bioinformatics Resources
Primer design
Primers for cloning in situ hybridization probes, for sequencing, and for testing MO efficacy
were designed using Primer349. Primers for quantitative PCR were designed using Universal
ProbeLibrary Assay Design Center (Roche).
In silico mutation analysis
Mutation Taster htto://www.mutationtaster.org57
PolyPhen2 http://genetics.bwh.harvard.edu/pph2/index.shtml58
SIFT http://sift.jcvi.org59
Provean http://provean.jcvi.org60
In silico promoter analysis
Analysis of SHOX P2 promoter for the identification of putative RARs and RXRs binding
sites was performed using PROMO53;54.
Databases
NCBI http://www.ncbi.nlm.nih.gov/
Ensembl Genome Browser http://ensembl.org/index.html
UCSC http://genome.ucsc.edu/
1000 genomes http://www.1000genomes.org
Exome Variant Server http://evs.gs.washington.edu/EVS/
ExAC Browser http://exac.broadinstitute.org
UniProtKB http://www.uniprot.org/help/uniprotkb
ExPASy http://www.expasy.org
ZFIN http://zfin.org
Illustrations
Figures were prepared using Adobe Illustrator CS2. Protein and DNA schemes were drawn
using Illustrator of Biological Sequences (IBS)55.
2.18 Statistics
Statistics were performed using GraphPad Prism version 5 for Windows (GraphPad Software,
La Jolla, California, USA).
Statement: Some of the description have been taken and adapted from the theses of former
PhD students in the lab (Dr. Carolin Wohlfarth and Dr. Slavil Peykov).
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3 Results
3.1 Genetic Analysis of Family 1
3.1.1 Family 1 pedigree
We recruited a three generation German family with five affected individuals displaying LWD
with dysmorphic signs and Madelung deformity. According to the pattern of transmission of
the trait, an autosomal dominant inheritance was hypothesized (Figure 3.1).
Figure 3.1: Family 1 pedigree. Filled symbol, LWD affected individual; slash, divorced; symbol
with a slash, deceased individual; red bar, individual with SHOX mutation; green bar, individual
with CYP26C1 mutation; +, wild type allele; N.A., DNA not available; arrow, index patient.
The index patient (Figure 3.1 individual III:2) showed mesomelic short stature with a
SD of -3.7 when first diagnosed. She started developing Madelung deformity at the age of 7
years old. At 8 years and 9 months, the proband started receiving growth hormone therapy.
After 4 years of GH therapy the height improved to -1.83 SD. Three female affected family
members, I:2, I:3, and II:7, presented with mesomelic short stature with an SD of -4.51,
-3.73 and -3.14, respectively. Moreover, these patients presented with Madelung deformity.
The father (II:3) of the proband showed also mesomelic short stature (SD = -2.63), and a
borderline Madelung deformity. The mother (II:4), an aunt (II:8), and the stepsister (III:1)
presented with short stature too, but did not show other skeletal abnormalities (Table 3.1).
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Patients ID Age Gender Height SD LA SD Madelung deformity
I:1 72 M -1.85 +0.57 No
I:2 72 F -4.51 -2.21 Yes
I:3 81 F -3.73 - Yes
II:1 51 M -1.23 - No
II:2 - F - - No
II:3 46 M -2.63 -2.00 (Yes)
II:4 42 F -3.33 -1.15 No
II:5 40 M -0.92 - No
II:6 - M - - No
II:7 37 F -3.14 - Yes
II:8 32 F -2.75 -1.50 No
III:1 21 F -3.73 -1.20 No
III:2 (proband) 8.9 F -3.6 -2.72** Yes
III:3 12.9 M -0.62 +0.10 No
III:4 8.5 F -1.96 -1.67 No
III:5 16 M -0.43 - No
III:6 16 M -0.72 - No
Table 3.1: Family 1 clinical data. M, male; F, female; -, data not available; Height SD, height
standard deviation; LA SD, lower arm standard deviation; Madelung deformity: Yes, present; No,
not present; (Yes), borderline; **, these data were taken at the age of 14 years.
3.1.2 SHOX locus analysis
Variants in the SHOX gene have been estimated to account for 70-90% of LWD. There-
fore, SHOX locus was analysed in this family first. A SHOX heterozygous missense variant,
c.482T>C (p.Val161Ala), was found by Sanger sequencing in the proband and her father.
Val161 is highly conserved among Shox vertebrate homologues and resides within the DNA
binding domain (Figure 3.2b, c). Functional analysis of this mutation in U2OS cells by lu-
ciferase assay on the FGFR3 promoter, a known SHOX target, demonstrated that it strongly
affects SHOX transcriptional activity (Figure 3.2d). When Sanger sequencing on the other
affected and non-affected family members was carried out, the SHOX mutation Val161Ala
was found in individuals with mild phenotype or normal stature too: the sister and two
cousins (Figure 3.1, individuals III:4, III:5 and III:6). Multiplex ligation-dependent probe
analysis (MLPA) was performed to exclude major genetic lesions in and around SHOX locus
(data not shown). Therefore, we asked whether there may be other genetic reason(s) which
may explain this variability.
56
Results
Figure 3.2: The SHOX variant identified in the family study affects its transcription
activity. (a) Sanger sequencing was used to validate the SHOX variant identified. (b) Alignment
of the amino acid sequences of vertebrate Shox proteins, showing the conservation of Val161. (c)
Schematic representation of SHOX protein. Val161 resides in the homeodomain. SH3, Src Homol-
ogy 3 domain. OAR, Otp Aristaless Rax domain. (d) Luciferase assay testing SHOX Val161Ala
mutation on FGFR3 promoter in U2OS cells (n=4). pcDNA4-TO empty vector was used as neg-
ative control. Arg153Leu was published as mutation affecting SHOX protein activity42 and was
therefore used as positive control. Data are shown as means ± SD; RLU, Relative Light Units; *
p-value = 0.0286, two-tailed Mann-Whitney non-parametric t test.
3.1.3 Whole-Genome Linkage analysis
Whole-genome linkage analysis was performed in collaboration with Dr. Gudrun Nuernberg
(Center for Molecular Medicine Cologne, Cologne, Germany) on the family members: I:1,
I:2, I:3, II:3, II:4, II:7, II:8, III:1, III:2, III:3, III:4, and III:6. This analysis identified linkage
disequilibrium with a max LOD score of 2.4 in a 19.2 Mb region of chromosome 10 (chr10:
85477515-104681710; hg19) (Appendix Figure 1 and Appendix Figure 2). The LOD
score obtained was the maximum expected for this family. This region encompasses 263 genes,
but could not be further refined. Moreover, we identified a 2.02 Mb sequence in the PAR1
region of chromosome X (chrX:706800-2735491; hg19) with a LOD score of 1.7 (Appendix
Figure 1 and Appendix Figure 3). This region localizes close to SHOX locus as expected.
The reason for the reduced LOD score in PAR1 are individuals III:4 and III:6 who carry the
disease haplotype although they are unaffected.
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3.1.4 Whole-exome sequencing analysis
The development of next-generation sequencing methodologies like whole-genome sequencing
(WGS) and whole-exome sequencing (WES) revolutionized the way of approaching candidate
genes identification. We decided therefore to adopt these technologies for this study. In
2012 whole exome sequencing analysis was performed in collaboration with Dr. Tim Strom
(Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany) on the
index patient and her father. Established methods were applied for variant filtering according
to the hypothesized autosomal dominant transmission of the phenotype56. A list of 98
variants in 97 genes was obtained (Appendix Table 1). All variants were tested using the
mutation prediction tools PolyPhen2, Mutation Taster, SIFT and PROVEAN, leading to 36
variants predicted as disease causing/damaging by at least one of these programs. Sanger
sequencing of the 36 variants was performed in affected and non-affected family members. I
found that only the mutations in OPN4 (chr10: 88419701-88419701; hg19) and CYP26C1
(chr10: 94828408-94828408; hg19) segregated with the phenotype. Both genes reside within
the chromosome 10 region as defined by linkage analysis. OPN4 is a member of the G protein-
coupled receptor superfamily involved in photoreception in the retina61. CYP26C1 encodes
for a member of the cytochrome P450 superfamily of enzymes involved in the catabolism of
RA62. RA was previously shown to play a key role in limb development63 and CYP26B1,
another member of the CYP26 family, is known to be involved in skeleton development64.
Moreover, RA has been previously shown to inhibit Shox expression in chicken limbs34.
Therefore we decided to further investigate CYP26C1 as a candidate modifier in SHOX
deficient short stature patients.
3.1.5 CYP26C1 Phe508Cys variant affects its enzymatic activity
In CYP26C1 a heterozygous missense variant was found, c.1523T>G (p.Phe508Cys), which
is highly conserved among vertebrates and was predicted as damaging by all four prediction
tools applied (Figure 3.3a-c). To assess whether this variant affects CYP26C1 enzymatic
activity, I performed the CignalTM RARE-System, a RA-responsive luciferase reporter assay,
in U2OS cells as described64. Over-expression of CYP26C1 wild type reduced the luciferase
activity, confirming that it degrades RA. The residue Cys459 is predicted by homology as
being the iron-binding amino acid. This residue was mutated to Ala to inhibit CYP26C1
catalytic activity; it was therefore used as positive control. This mutant showed significantly
reduced RA catabolic activity as expected (Figure 3.3d). The CYP26C1 Phe508Cys mutant
was not able to reduce luciferase activity when compared to the wild type form, suggesting
that this variant impairs CYP26C1 enzymatic activity (Figure 3.3d).
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Figure 3.3: The CYP26C1 variant identified in the family study affects its enzymatic
activity. (a) Sanger sequencing was used to validate the CYP26C1 variant identified. (b) Align-
ment of the amino acid sequences of vertebrate CYP26C1 proteins, showing the conservation of
Phe508. (c) Scheme of CYP26C1 protein. TM, Transmembrane helix; Cys459 represents the Iron
binding residue. (d) Cignal-RARE system luciferase assay testing CYP26C1 Phe508Cys mutation
in U2OS cells treated with 250 nM RA for 24h (n=4). pIRES2-EGFP empty vector was used
as control. The iron binding residue Cys459 was mutated to Ala as positive control. Data are
shown as means ± SD; RLU, Relative Light Units; * p-value = 0.0286, two-tailed Mann-Whitney
non-parametric t test.
3.2 Screening of further LWD and ISS individuals
To find out whether the co-occurrence of SHOX and CYP26C1 variants in severe phenotypes
is a unique finding specific only to family 1, we screened CYP26C1 in a cohort of 68 individ-
uals with LWD and in a cohort of 140 controls with normal height where SHOX deficiency
was excluded. The complete list of the variants identified can be found in Appendix Table
2. Synonymous, intronic and common variants were excluded from further analysis.
We identified two further cases with co-occurrence of SHOX and CYP26C1 variants (Figure 3.4).
Available clinical data are listed in Table 3.2.
Family 2 had one affected daughter (II:2) presenting with short stature, mesomelia and
Madelung deformity. The sister (II:1) presented with short stature but skeletal dysmorphis
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were not diagnosed. Both parents presented with normal stature and no dysmorphisms. A
heterozygous SHOX missense mutation c.394C>G (p.Leu132Val) was found in the unaffected
father and the two siblings. This variant was previously shown to alter homodimerization and
reduce DNA binding abilities42. Screening of CYP26C1 identified a heterozygous missense
mutation c.1133G>A (p.Arg378His) only in the affected daughter (Figure 3.4a, Family 3).
The third case was a girl with short stature, mesomelia and Madelung deformity carrying
a de novo heterozygous deletion of SHOX and a missense variant in CYP26C1, c.356A>C
(p.Gln119Pro). Both parents and the brother were reported having normal stature. The
CYP26C1 variant was inherited by the father. Since the SHOX deletion is de novo, this
family cannot demonstrate specific co-segregation although it adds to overall evidence that
damaging variants in SHOX and CYP26C1 co-occur in individuals with severe LWD pheno-
types (Figure 3.4a, Family 2).
Functional analysis of the SHOX and CYP26C1 variants found in these two cases demon-
strated their negative impact on the protein activity (Figure 3.4b and c). We conclude
that, in addition to family 1, two out of 68 LWD patients with SHOX deficiency presented
with damaging variants in CYP26C1 while no damaging mutations were identified in 140
control individuals with normal height. In all families where clinical information was avail-
able, all individuals with damaging mutations in both SHOX and CYP26C1 had the more
severe skeletal phenotype.
Screening of the controls lead to the identification of common synonymous and intron variants.
The variants found are listed in Appendix Table 3.
Family Patients ID Age Gender SD LA SD Madelung deformity
Family 2
I:1 - M - - No
I:2 - F - - No
II:1 - F - - No
II:2 6 F -3.38 -4.71 Yes
Family 3
I:1 51 M +0.1 - No
I:2 47 F +0.8 -0.1 No
II:1 26 M +0.5 -0.9 No
II:2 16 F -2.6 -3.6 Yes
Table 3.2: Families 2 and 3 clinical data. M, male; F, female; -, data not available; Height
SD, height standard deviation; LA SD, lower arm standard deviation.
Finally, in order to test whether CYP26C1 mutations alone could lead to short stature or
dysmorphic signs, a group of 256 affected individuals (234 ISS and 22 LWD), where SHOX
deficiency was excluded, was screened with the GS Junior System (Roche). The variants
found are available in Appendix Table 4. We identified two rare missense variants in two
independent ISS individuals, c.148C>T (p.Pro50Ser) and c.356A>C (p.Gln119Pro) predicted
as damaging (Figure 3.5a and b). Phenotypic information of the family carrying the variant
c.148C>T (p.Pro50Ser) were not available. Functional analysis of this variant did not show
any significant effect on protein activity (Figure 3.5c). Variant c.356A>C (p.Gln119Pro)
was found in a family with three affected siblings. Based on the inheritance of the trait, we
obtained no convincing evidence that this variant alone is causative for short stature, although
the mutation segregated with the most affected individuals and showed a significant impact
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on CYP26C1 catabolic activity (Figure 3.5a and c). Altogether, these genetic data do
not support the hypothesis that CYP26C1 alone is causative for short stature or skeletal
abnormalities.
Figure 3.4: Family pedigree charts of the screened LWD patients and functional analysis
of the identified variants. (a) Pedigree of the LWD families carrying variants in both SHOX
and CYP26C1. Filled symbol, short stature affected individual; red text, SHOX locus; green
text, CYP26C1 locus; +, wild type allele; N.A., DNA not available; *, individual with mesomelia
and Madelung deformity. (b) Scheme of SHOX protein (upper panel). Leu132 resides in the
homeodomain. Luciferase assay testing SHOX Leu132Val mutation on FGFR3 promoter in U2OS
cells (n=4). pcDNA4-TO was used as control. Arg153Leu was published as mutation affecting
SHOX protein activity and was therefore used as positive control. Data are shown as means ± SD;
RLU, Relative Light Units; *** p-value < 0.001, one-way ANOVA Bonferroni’s multiple comparison
test. SH3, Src Homology 3 domain. OAR, Otp Aristaless Rax domain. (c) Scheme of CYP26C1
protein. Gln119 and Arg378 reside within the P450 domain. Cignal-RARE system luciferase assay
testing CYP26C1 Gln119Pro and Arg378His mutations in U2OS cells treated with 250 nM RA for
24 hours (n=4). pIRES2-EGFP was used as control. The iron binding residue Cys459 was mutated
to Ala as positive control. Data are shown as means ± SD; RLU, Relative Light Units; * p-value
= 0.0286, two-tailed Mann-Whitney non-paramtric t test. TM, Transmembrane helix.
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Figure 3.5: Family pedigree charts of the screened ISS and LWD individuals and func-
tional analysis of the identified mutations. (a) Pedigree of the families studied. Filled symbol,
short stature affected individual; slash, divorced; green text, CYP26C1 locus; +, wild type allele;
N.A. DNA not available; arrow, index patient. (b) Scheme of CYP26C1 protein. Pro50 and Gln119
reside within the P450 domain. TM, Transmembrane helix. Cys459 represents the Iron binding
residue. (c) Cignal-RARE system luciferase assay testing CYP26C1 Pro50Ser and Gl119Pro muta-
tions in U2OS cells treated with 250 nM RA for 24 hours (n=4). pIRES2-EGFP was used as control.
The iron binding residue Cys459 was mutated to Ala as positive control. Data are shown as means
± SD; RLU, Relative Light Units; * p-value = 0.0286, two-tailed Mann-Whitney non-paramtric t
test.
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3.3 Functional Studies in Human Cells
3.3.1 CYP26C1 is expressed in human primary chondrocytes
To investigate whether CYP26C1 is expressed in human primary chondrocytes similar to
SHOX PCR was performed on cDNA and products corresponding to the predicted size were
obtained (Figure 3.6a). Sanger sequencing of these bands confirmed that they correspond
to the CYP26C1 transcript. Western blotting analysis were performed to assess CYP26C1
expression at the protein level. As control to verify band sizes, recombinant CYP26C1 was
overexpressed in U2OS cells. CYP26C1 protein is reported to be expressed in the microsomes.
Therefore, citosolic and microsomal protein fractions from human primary chondrocytes were
obtained. Immuno blotting of human primary chondrocytes confirmed CYP26C1 expression
(Figure 3.6a).
3.3.2 CYP26C1 and SHOX are part of the RA pathway
It has been previously shown that RA can down-regulate SHOX expression in the developing
limbs in chicken embryos34. Therefore we asked whether RA could affect SHOX expression
in human primary chondrocytes. Treatment of primary chondrocytes with 10-50 nM of all-
trans retinoic acid (ATRA) did not lead to a significant effect on SHOX mRNA expression
(Figure 3.6b). Treatment with 100 nM ATRA resulted in a significant reduction of SHOX
levels (Figure 3.6b). Hence, high levels of ATRA decrease SHOX expression in human
chondrocytes.
To test whether RA regulates SHOX expression by a direct binding of RARs or RXRs to the
promoter region, I cloned the P2 promoter together with the CNE3 enhancer as previously
described33. SHOX promoter P1 was also tested, but even under the CNE3 enhancer did
not show any activation of the firefly luciferase when compared to the empty vector (data not
shown). CNE3 was chosen as enhancer because it was reported with the strongest activity
over luciferase expression (Verdin et al., 2015). Treatment of the CNE3-P2 construct with
ATRA led to a significant reduction of luciferase expression (Figure 3.6c), corroborating
the hypothesis that RA regulates SHOX expression. In order to elucidate whether RA
regulation occurs via direct or indirect mechanisms, in silico analysis of putative transcription
factors binding sites was performed. This analysis identified three putative RXRα binding
sites. Site-specific mutation of these sequences did not change ATRA effect on luciferase
expression suggesting that an indirect regulation takes place (Figure 3.6c). These results
provide evidence that CYP26C1 and SHOX are members of the same pathway: CYP26C1
regulates SHOX expression by regulating retinoic acid intracellular levels (Figure 3.6d).
Further analyses need to be carried out to elucidate the molecular mechanisms underlying
such regulation.
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Figure 3.6: CYP26C1 and SHOX are part of the RA signalling pathway. (a, left panel)
RT-PCR showing the expression of CYP26C1 mRNA in human primary chondrocytes. SOX9 was
used as chondrocyte marker. (a, right panel) Western blot showing the expression of CYP26C1
in human primary chondrocytes on protein level. Overexpression of CYP26C1 in U2OS cells was
carried out to compare band sizes. CYP26C1 protein is expressed in human primary chondrocytes
microsomes. +, cDNA; -, water; M, marker; HPC, human primary chondrocytes. (b) Relative
expression of SHOX mRNA normalized to the housekeeping genes SDHA and HPRT in human
primary chondrocytes treated with all-trans retinoic acid (ATRA) 10 nM or 100 nM for 6h (n=5).
Data are shown as means ± SD; n.s., not significant, ** p-value = 0.0079, two-tailed Mann-Whitney
non-parametric t test. (c) In silico analysis of SHOX P2 promoter identified three putative RXRα
binding sites which were mutated to test their direct effect on SHOX expression regulation upon
treatment with ATRA 250 nM (n=4). Data are shown as means ± SD; RLU, relative luciferase
unit; * p-value = 0.0286, n.s., not significant, two-tailed Mann-Whitney non-parametric t test. (d)
CYP26C1 and SHOX are members of the RA pathway. Vitamin A, retinol (ROL), enters the cell
and is oxidized to retinaldehyde (RAL). RAL is then oxidized to retinoic acid (RA). RA can enter
the nucleus and regulate the expression of its targets. CYP26C1 controls RA intracellular levels
by oxidizing this molecule in more hydrosoluble retinoids molecules like 4’-hydroxy-retinoic acid
(4’-OH-RA), which can be readily excreted out of the cell. High levels of RA downregulate SHOX
expression.
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3.4 Functional Studies in Zebrafish Embryos
3.4.1 Morpholino efficacy analysis
Human pathologies have mostly been modelled using mammal systems such as mice. How-
ever, mice do not have any Shox orthologue. Therefore, we decided to use zebrafish (Danio
rerio) as model in collaboration with Dr. David Hassel (Department of Internal Medicine
III - Cardiology, Heidelberg University Hospital, Heidelberg, Germany). Zebrafish has been
extensively used as model organism well suited to developmental and genetic analysis. The
advantages of zebrafish as model are: high genetic and organ system homology to humans,
high fecundity, external fertilization, ease of genetic manipulation, and transparency through
early adulthood that enables imaging analysis of most tissues. Morpholino oligonucleotides
(MOs) are the most used anti-sense knockdown tools in zebrafish. MOs have demonstrated to
be useful in probing candidate gene function, and testing mutant phenotypes. Hence, to gain
insight into the role of Shox and Cyp26c1 interaction on limb development, we performed
antisense MO knockdown experiments in zebrafish embryos.
Human and zebrafish Shox and Cyp26c1 proteins share a 65% and 54% identity, respectively.
Both genes have been shown to be expressed in pectoral fins65;66. The shox and cyp26c1
morpholinos were obtained from Gene Tools; sequences are available in the Materials and
Methods chapter. Knockdown of shox was obtained using the splicing MO, MO1; phenotype
specificity was confirmed using a second splicing MO, MO2. MO1 only was used for in
situ hybridization analysis and double knockdown experiments. Knockdown efficacies are
shown in Figure 3.7 and Figure 3.8. Knockdown of cyp26c1 was obtained using an already
published MO67. Efficacy is shown in Figure 3.9.
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Figure 3.7: shox MO1 efficacy analysis. (a) Scheme of shox unspliced mRNA. Red bar, region
targeted by shox MO1; arrows, position of the primers to analyse MO efficacy; f, forward primer;
r, reverse primer. (b) RT-PCR analysis of shox MO1 efficacy. The 430 bp band represents the
expected wild type product. Water was used as negative control (-) for the PCR. Samples were
obtained from 48hpf embryos. (c) RT-PCR products were cloned in pUC19 and sequenced. shox
MO1 leads to a spliced product leading to frameshift, p.L142Rfs37*. Black vertical segments enclose
the out-spliced sequence.
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Figure 3.8: shox MO2 efficacy analysis. (a) Scheme of shox unspliced mRNA. Red bar, region
targeted by shox MO2; arrows, position of the primers to analyse MO efficacy; f, forward primer;
r, reverse primer. (b) RT-PCR analysis of shox MO2 efficacy. The 680 bp band represents the
expected wild type product. Water was used as negative control (-) for the PCR. Samples were
obtained from 48hpf embryos. (c) RT-PCR products were cloned in pUC19 and sequenced. shox
MO2 leads to a spliced product leading to frameshift, p.V59Pfs11*. Black vertical segments enclose
the out-spliced sequence.
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Figure 3.9: cyp26c1 MO efficacy analysis. (a) Scheme of cyp26c1 unspliced mRNA. Red bar,
region targeted by cyp26c1 MO; arrows, position of the primers to analyse MO efficacy; f, forward
primer; r, reverse primer. (b) RT-PCR analysis of cyp26c1 MO efficacy. The 530 bp band represents
the expected wild type product. Water was used as negative control (-) for the PCR. Samples were
obtained from 48hpf embryos. (c) RT-PCR products were cloned in pUC19 and sequenced. cyp26c1
MO leads to the exclusion of exon 3. Black vertical segments enclose the out-spliced sequence.
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3.4.2 shox MO knock-down phenotype
We first assessed the effect of shox knockdown. Upon shox MO injection, the zebrafish
embryos showed an overall delayed growth and a strong impairment of pectoral fins devel-
opment (Figure 3.10a and b). shox reduction with MO2 led to similar resutls (Figure
3.11). Similar results have been reported in another zebrafish shox knockdown model65.
Antisense probe staining of sox9, a known marker of chondrocytes, clearly shows the dra-
matic pectoral fins phenotype caused by shox knockdown (Figure 3.10c), although we did
not observe any significant change in the expression. Staining of col2a1, another marker
of chondrocytes, shows that its expression is missing specifically in the shox MO injected
embryos (Figure 3.10d). Finally, pectoral fin areas were measured using ImageJ. We found
a dramatic reduction of the pectoral fins suggesting that shox role in limb development is
highly conserved among vertebrates (Figure 3.10e).
Figure 3.10: Pattern of defects in zebrafish embryos injected with anti-shox mor-
pholino. Pattern of defects in zebrafish embryos injected with anti-shox morpholino. (a-c) Wild-
type embryos injected with control MO or injected with 1-2 ng shox MO. (a) Lateral views of the
embryos at 55 hpf (hours post fertilization). (b) Dorsal view and magnification on the lateral view
of the embryos. White dots mark the pectoral fins. shox morphants show smaller fins compared to
controls (n=30 embryos). (c and d) Expression at 55 hpf of sox9 and col2a1 was examined by in
situ hybridization in wild-type embryos injected with control MO and with shox MO. Black dots
mark the protruding pectoral fin. (d) Pectoral fins area was measured by imageJ (n=30 embryos).
Data are shown as means ± SD; *** p-value = 0.0001, two-tailed unpaired Student’s t test.
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Figure 3.11: Validation of shox MO1 pattern of defects with shox MO2. Wild type
embryos injected with control MO or with shox MO2 (n=30 embryos). Dorsal view of the embryos
at 55 hpf. Dotted line, pectoral fins.
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3.4.3 cyp26c1 MO knock-down phenotype
We then analyzed the effect of cyp26c1 knockdown in zebrafish embryos. Injection of cyp26c1
MO resulted in a significant reduction of pectoral fins size (Figure 3.12a and b). Moreover,
the embryos showed an abnormal development of the otic vesicles and pharyngeal arches, and
a pericardial edema (Figure 3.12a and b). In situ hybridization of sox9 revealed a stronger
expression upon cyp26c1 MO injection (Figure 3.12c). On the other hand, expression anal-
ysis of shox was decreased upon cyp26c1 knockdown (Figure 3.12e) which was confirmed
by quantitative PCR (Figure 3.13c). Expression of col2a1 was overall reduced, and absent
in the pectoral fins (Figure 3.12d).
Figure 3.12: Pattern of defects in zebrafish embryos injected with anti-cyp26c1 MO.
(a-e) Wild-type embryos injected with control MO or injected with 1-2 ng of cyp26c1 MO. (a)
Lateral views of the embryos at 55 hours post fertilization (hpf). (b) Dorsal view and magnification
on the lateral view of the embryos. White dots mark the pectoral fins. Arrows indicate the otic
vesicles. cyp26c1 morphants show smaller fins compared to controls (n=40). (c-e) Expression at
55 hpf of sox9, col2a1 and shox were examined by in situ hybridization in embryos injected with
control MO or with cyp26c1 MO. (c) Dorsal view and magnification on the pectoral fins of sox9
expression . (d) Dorsal view and magnification on the pectoral fins of col2a1 expression. (e) Dorsal
view and magnification on the pectoral fins of shox expression. Black dots mark the protruding
pectoral fin.
Pectoral fins areas were measured using ImageJ. Knockdown of cyp26c1 led to a significant
reduction of the pectoral fins (Figure 3.13a). Moreover, we tested whether CYP26C1 regu-
lates RA levels in zebrafish embryos by co-injecting control or cyp26c1 MO together with the
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Cignal RARE-System assay. In accordance with a role of CYP26C1 in RA degradation, MO
knockdown of this gene led to a significant increase of RA levels compared to control MO
(Figure 3.13b). Finally, we tested whether RA downregulates Shox expression in zebrafish
embryos as observed in human primary chondrocytes and chicken limb buds. Treatment of
zebrafish embryos with 50 nM did not lead to a decrease of shox expression, whereas treat-
ment with 100 nM significantly reduced shox transcripts. Altogether these data suggest that
CYP26C1 plays a role in limb development by exerting its control over RA levels. Moreover,
this model further corroborate the hypothesis that CYP26C1 deficiency leads to an excess
of RA which induces a downregulation of SHOX expression.
Figure 3.13: Pattern of defects in zebrafish embryos upon MO reduction of cyp26c1
and RA treatment. (a) Pectoral fins area was measured by imageJ (n=30 embryos). Data are
shown as means ± S.D.; ** p-value = 0.0119, two-tailed unpaired Student’s t test. (b) Cignal-
RARE system luciferase assay testing cyp26c1 MO on RA acid levels in zebrafish embryos (n =
20-30 embryos, n = 4 replicates) . Data are shown as means ± SD; RLU, Relative Light Units; *
p-value = 0.0286, two-tailed Mann-Whitney non-parametric t test. (c) Relative expression of shox
mRNA normalized to those of housekeeping genes eef1α and β-actin zebrafish embryos injected
with control MO or cyp26c1 MO (n=20-30 embryos, n=3 replicates). Data are shown as means ±
SD; * p-value = 0.0286, two-tailed Mann-Whitney non-parametric t test.
3.4.4 Double shox and cyp26c1 MO knock-down phenotype
To further test the hypothesis that CYP26C1 is a modifier of SHOX deficiency, we co-injected
shox and cyp26c1 MOs. Injections were performed using concentrations of shox and cyp26c1
MOs titrated down to the effect that single knockdown of shox or cyp26c1 MO did not lead
to a reduction of the pectoral fins. Upon double knockdown of shox and cyp26c1, a significant
reduction of the pectoral fins was observed (Figure 3.14a). Staining of sox9 clearly showed
the pectoral fins impairment, although difference in the expression of this marker could not
be observed (Figure 3.14b). Staining of col2a1 displayed the pectoral fins reduction and
decrease of its expression (Figure 3.14c).
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Figure 3.14: Pattern of defects in zebrafish embryos co-injected with anti-shox and
anti-cyp26c1 MOs. Wild-type embryos injected with control MO, subphenotypic doses of shox
MO (100 pg), cyp26c1 MO (800 pg) or a combination of shox/cyp26c1 MOs. (a) Lateral view,
dorsal view and magnification on the lateral view of the embryos at 55 hpf (hours post fertilization).
White dots mark the pectoral fins. shox/cyp26c1 double morphants show smaller fins compared
to control and single MOs (n=20-30 embryos). (b and c) Expression at 55 hpf of sox9 and col2a1
was examined by in situ hybridization. Dorsal view and magnification on the pectoral fins of sox9
and col2a1 expression is shown. Black dots mark the protruding pectoral fin.
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Pectoral fins areas were measured by ImageJ. Double knockdown resulted in a signifi-
cant reduction of the fins (Figure 3.15a). Finally, shox expression was measured by quan-
titative PCR. Double knockdown led to a significant decrease of shox mRNA expression
(Figure 3.15b). Altogether, these data corroborate the hypothesis that co-occurrence of
SHOX and CYP26C1 deficiency leads to severe short stature phenotypes.
Figure 3.15: Double MO knockdown of shox and cyp26c1 leads to reduced pectoral
fins. (a) Pectoral fins area was measured by imageJ (n=20-30 embryos). Data are shown as
means ± SD; *** p-value = 0.0001, one-way ANOVA Bonferroni’s multiple comparison test. (b)
Relative expression of shox mRNA normalized to those of housekeeping genes eef1α and β-actin
zebrafish embryos injected with control MO, shox MO, cyp26c1 MO, or shox/cyp26c1 MOs (n=20-
30 embryos, n=3 replicates). Data are shown as means ± SD; ** p-value = 0.0048, Klustal-Wallis
Dunn´s multiple comparison test.
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4 Discussion
Identification of CYP26C1 as a genetic modifier for SHOX deficiency
Phenotype is the result of the relationship between genotype and environment. It has al-
ways been of interest to understand how this relationship leads to the phenotypic variability
among individuals. Since a phenotype depends on the genotype inherited and since geno-
types are easier to tackle than environmental factors, scientists have been mainly focusing on
the inheritance of genes to explain specific traits. Many genotypes have been associated to
specific phenotypes, however, several studies have reported that a certain genotype does not
always lead to the same or related phenotype. For many Mendelian diseases, the identical
mutation does not always lead to the same disease phenotype in all individuals who carry it.
Some individuals may express a mild phenotype; others a very severe one. Some individuals
will never develop the disease; others may be diagnosed at an early age. Based on these
observations, already in 1926 Oskar Vogt introduced the terms "penetrance" and "expres-
sivity" as measures of the percentage of individuals in which the genotype is expressed in
phenotype and the degree of expression, respectively. Incomplete penetrance and variable
expressivity can be explained by the interactions between the genotype correlated to the
expected phenotype and genetic and/or environmental factors. The genetic factors, usually
addressed as "genetic background", have been indicated as modifier genes: loci that can alter
the phenotypic output of another gene68. In the literature, only few cases of modifier genes
of human phenotypes have been reported, although there are many examples in laboratory
mice. Modification can occur at different levels, from a direct effect on the transcription of the
target gene, through intermediate phenotypes at the molecular level such as protein-protein
interactions, to phenotypes at the level of the whole organism.
Modifier genes may lead to more severe, less severe, novel or wild-type phenotypes by affect-
ing penetrance, expressivity, dominance and pleiotropy68. Taken a population of individuals
carrying a particular genotype, penetrance indicates the frequency of individuals presenting
with the associated phenotype. Unaffected individuals carrying the disease genoytpe give ev-
idence of reduced penetrance. One example of modifier genes affecting penetrance in human
is the case of non-syndromic deafness. Individuals carrying homozygous mutations in the
gene DFNB26 usually present with non-syndromic hearing loss. However, individuals with
deficiency of DFNB26 but normal hearing have been identified. A dominant not yet defined
modifier on chromosome 7 protects these individuals from hearing loss, leading to reduced
penetrance68.
Expressivity describes the extent to which a certain genotype is expressed in the respective
phenotype. A disease phenotype may be more severe, mild or even suppressed to seem almost
normal. One example of a modifier gene that reduces expressivity is the case of familial hy-
percholesterolalemia. Genetic studies have identified a region on chromosome 13q as bearing
a modifier that reduces LDL levels protecting from hypercholesterolemia68.
Dominance of a genotype depends on many variables such as allele, genetic background and
environmental factors. A phenotype can be inherited in a dominant manner, but behave as
recessive on a certain genetic background or vice versa. An example of a genetic modifier
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affecting dominance is the case of the PRP1 gene. Homozygous mutations in PRP1 lead
to retinitis pigmentosa indicating that this phenotype is inherited in a recessive manner.
However, there are individuals who bear PRP1 heterozygous mutations but also develop the
disease. It has been shown that variants in an independent gene, ROM1, modify the retinitis
pigmentosa phenotype from a recessive trait to a dominant one in PRP1 heterozygous indi-
viduals68.
Pleiotropy describes mutations in single genes which lead to diverse phenotypic effects. In-
dividuals with the same genotype may present different combinations of disease phenotypes
depending on the genetic background. Individuals carrying damaging mutations in both the
alleles of the pyrin/marenostrin gene present with familial Mediterranean fever. Some indi-
viduals with this condition may also be affected by complications like renal amyloidosis. A
variant in the gene serum amyloid A has been associated with amyloidosis in individuals with
familial Mediterranean fever68.
In this PhD project I describe SHOX deficiency, a Mendelian disorder with wide pheno-
typic variability which provides a unique opportunity to identify the genetic causes of such
variability. The whole idea shaped when we studied a large family with LWD affected indi-
viduals (Figure 3.1). Screening SHOX gene in this family led to the identification of the
variant p.Val161Ala in the five affected individuals. This variant showed a strong effect on
SHOX transactivation activity (Figure 3.2), therefore we thought that the diagnosis was
ready to be communicated to the family. Surprisingly, we identified three family members
carrying the damaging variant but presenting with normal stature and no skeletal dysmor-
phisms. This finding prompted us to postulate genetic modifier effects as the possible reasons
for such phenotypic variability. In order to identify potential genetic modifiers, we combined
whole genome linkage and whole exome sequencing analysis in the family and found a variant
in CYP26C1 co-segregating with the clinical phenotype.
Screening of 68 further unrelated individuals with LWD and damaging variants in SHOX,
led to the identification of two further unrelated cases presenting with mutations in both
SHOX and CYP26C1 (Figure 3.8). Family 2 was of paramount importance to corroborate
our hypothesis. Individual I:1 (the father) was asymptomatic despite bearing a damaging
mutation within the SHOX homeodomain, p.Leu132Val. The unaffected daughter (II:1) was
described with short stature and carrying the missense SHOX variant, but dysmorphic signs
were not reported. The daughter presenting the more severe phenotype in this family, carried
also a CYP26C1 variant, p.Arg38His. The mother (I:2) was also normal stature and most
likely carried the CYP26C1 damaging variant; DNA from this individual was not available to
confirm inheritance. The third case was a girl carrying a deletion of SHOX and a damaging
missense variant in CYP26C1. This patient presented with severe dysproportionate short
stature and Madelung deformity. Her parents and the brother were reported with normal
stature. The SHOX deletion was confirmed by MLPA analysis only in the daughter indicat-
ing that it is a de novo event. Therefore, it is possible that the deletion alone is sufficient
to lead to the observed phenotype. Although the identified CYP26C1 heterozygous variant
cannot demonstrate specific co-segregation, it adds to overall evidence that damaging vari-
ants in SHOX and CYP26C1 co-occur in individuals with severe LWD phenotypes.
Hence, in addition to family 1 we identified two out of 68 unrelated patients with SHOX
deficiency and damaging mutations in CYP26C1. No damaging mutations in CYP26C1 were
found in 140 controls. No individuals from our cohort was found with deleterious variants
in both genes. Moreover, we screened TGP for individuals carrying damaging mutations in
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both SHOX and CYP26C1. TGP is an international research effort that has the most de-
tailed catalogue of human genetic variation available to the public so far. TGP assigns a code
to each genome. It is therefore possible to track every variant identified in each individual
genome present in this database. Most of the SHOX variants described in TGP are associ-
ated with short stature, but it is not possible to retrieve the individual code. However, for
some SHOX variants it is possible to retrieve the individual code. I selected those individuals
carrying SHOX damaging variants and asked whether they bear damaging variants also in
CYP26C1. No individual from the TGP database was found to carry damaging variants
in both genes. Altogether, these data suggest that co-occurrence of SHOX deficiency and
damaging mutations in CYP26C1 in LWD patients is not coincidental.
CYP26C1 exerts its modifier effects by regulating SHOX expression through
the control of RA levels
CYP26C1 is an enzyme belonging to the cytochrome P450 superfamily and is involved in
the oxidation of RA to generate polar retinoid species which are readily excreted. Thus,
CYP26C1 is involved in the catabolism of RA62. Accordingly, we found that damaging mu-
tations in CYP26C1 reduce its RA catabolizing activity leading to a higher concentration of
this retinoid in U2OS cells (Figure 3.6d and 3.8c).
RA exerts its function by regulating the transcriptional activity of nuclear retinoic acid
receptors (RARs). RARs heterodimerize with retinoic X receptors (RXRs) to function as
transcription factors. Binding of RA to these receptors triggers activation or repression of
their target genes4. RA plays a key role in development, including formation of the body
axis and skeleton63. During skeletal development, RA coordinates the development of cen-
tral body axis, limb axis and cranium. Moreover, it controls chondroblast differentiation and
coordinates maturation and replacement of bone tissue during endochondral ossification4.
RA also plays a role in the post-natal maintenance of bone6. An excess or a deficiency of
RA dysregulate the expression of the respective target genes, which has a dramatic effect
on development4. Excess or deficiency of RA have, for example, been shown to impair limb
development in zebrafish and mice embryos69–73. Hence, a tight regulation of RA metabolism
is essential.
We demonstrated for the first time that CYP26C1 is expressed on RNA and protein level
in human primary chondrocytes (Figure 3.7a), suggesting a role for CYP26C1 in the fine
regulation of RA in these cells. It would be interesting to test whether loss of function of this
gene in primary chondrocytes, e.g. by genome editing with the CRISPR-Cas9 system, leads
to a higher sensitivity to exposure to excess of RA. I tested several transfection reagents and
nucleofection to introduce external DNA inside primary chondrocytes. Former lab members
also tried similar approaches several years ago. Only lentiviral transduction proved to be
successful, although low efficiency was observed (PD Dr. Antonio Marchini, personal com-
munication).
Damaging variants in CYP26C1 that affect its RA oxidation activity may lead to high
levels of this retinoid. Previous experiments on chicken limbs have shown that treatment
with excess RA strongly reduces Shox expression34. Consistent with a role of RA in SHOX
regulation, we have shown that treatment of human primary chondrocytes and zebrafish
embryos with a concentration of 100 nM RA significantly reduced Shox mRNA expression
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(Figure 3.7b and 3.16). Shox transcription was not significantly affected by 10-50 nM RA,
suggesting that a main function of CYP26C1 is to protect cells from the effect of excessive
RA on its target genes expression. In support of this hypothesis, we found that knockdown
of cyp26c1 in zebrafish embryos increased RA levels, reduced col2a1 and shox expression
and upregulated sox9 expression (Figure 3.15 and 3.16). Sox9 is a key transcription fac-
tor necessary for the differentiation of mesenchymal progenitors into chondrocytes. Sox9 is
highly expressed in chondroblasts and proliferative chondrocytes and is downregulated dur-
ing hypertrophy. Col2a1 is a major component of cartilage matrix during the early stages
of endochondral differentiation. Shox is a transcription factor which is expressed in rest-
ing, proliferative and terminally differentiated hypertrophic chondrocytes. High expression
of SHOX can be observed in the hypertrophic region. We showed that the increase in RA
levels induced by cyp26c1 knockdown in zebrafish embryos alters the expression of different
genes. Upregulation of sox9 and downregulation of col2a1 and shox, among the genes which
are dysregulated by high levels of RA, may lead to inhibition of hypertrophy and delayed
or defective ossification. These cellular phenotypes eventually may manifest with shortened
limbs and dysmorphic signs like Madelung deformity.
In order to test whether RA reduces SHOX expression directly or indirectly, I performed
in silico analysis of SHOX locus. Several putative binding sites were identified both in the
promoter regions and in introns. I decided to focus the analysis on the published P1 and P2
promoter. To test RA effect on these sequences, I cloned P1 and P2 in the pGL3basic vector
together with the CNE3 enhancer and performed luciferase assays in U2OS cells. P1 did
not show any effect on luciferase expression (data not shown). The P2 promoter, however,
induced luciferase expression in U2OS cells as previously shown33. Interestingly, treatment
with ATRA led to a significant reduction of luciferase activity. These data suggest that P2 is
regulated by RA. To verify whether this was a direct or indirect effect, I mutated the three
putative RXRα binding site identified in P2. Luciferase downregulation upon RA treatment
did not significantly change in this mutant suggesting that RA regulation of P2 does not
depend on this DNA sequence but rather RA exerts an indirect effect. Further analysis
is needed to clarify the molecular mechanisms by which RA exerts its control over SHOX
expression regulation. It would be interesting, for example, to perform reverse chromatin
immunoprecipitation assays coupled with mass spectometry analyses to identify potential
regulators of SHOX expression upon RA treatment.
Is there an interaction between RA and estrogen signalling over SHOX
expression regulation?
Several studies have reported that mesomelia and Madelung deformity are more severe in
adult females than in children or adult males. Madelung deformity is difficult to diagnose
in prepubertal patients, although slight mesomelia and subtle dysmorphisms are usually ob-
served in LWD individuals46. The mother (II:4), an aunt (II:8) and the stepsister (III:1)
of the index patient (III:2) in family 1 presented, for example, short stature but dysmor-
phic skeletal signs were not diagnosed. These individuals did not carry damaging variants
neither in SHOX nor in CYP26C1, suggesting that different factors contribute to the short
stature phenotype observed in these family members. Mesomelia and Madelung deformity
phenotypes were present only in those individuals carrying damaging variants in SHOX and
CYP26C1 in the three families identified in this study.
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We also reported male individuals in family 1 (III:5, III:6) and family 2 (I:1) with damaging
SHOX variants but normal stature. Hence, gender bias could explain the reported severe
phenotypes in the affected individuals in these two families independently of CYP26C1. How-
ever, in family 1 the father (II:3) of the index patient (III:2) presented with short stature,
mesomelia and borderline Madelung deformity, and bore damaging variants in both SHOX
and CYP26C1. The sister (III:4) of the index patient (III:2) presented with height within
the normal range and no skeletal phenotype, and had only the SHOX damaging variant. In
family 2, the sister (II:1) of the patient presented with short stature but neither mesomelia
nor Madelung deformity were identified; she bore only the damaging variant in SHOX. To-
gether, these data suggest that damaging missense variants in CYP26C1 play an important
role as modifiers of SHOX deficiency towards more severe dysmorphic phenotypes. Since
in family 1 the father (II:3) of the index patient (III:2) presented with milder mesomelia
and borderline Madelung deformity, it is obvious that gender exerts a modifier effect on
SHOX deficiency even in presence of CYP26C1 damaging variants. We cannot exclude that
the non-affected daughters in family 1 and 2 bearing only the SHOX variants will develop
dysmorphic phenotypes during puberty. Noteworthy, diagnoses of the affected daughters in
family 1 and 2 bearing damaging variants both in SHOX and CYP26C1 identified severe
phenotypes already before puberty (Table 3.1 and 3.2).
It has been suggested that gonadal estrogens aggravate effects in patients with SHOX
deficiency by enhancing premature epiphyseal fusion17. In support to this hypothesis, a
combination of SHOX overdosage and gonadal estrogen deficiency has been associated to
tall stature25.
The males reported in this thesis presented with normal or milder SHOX deficiency phe-
notypes even in the presence of damaging variants in CYP26C1, in accordance with the
aforementioned observation that LWD affects more females than males.
Estrogens exert their function through the regulation of the estrogen receptors (ERs) tran-
scription factors ERα and ERβ. Studies in breast cancer reported that RARα and ERα
interact to regulate gene expression. In particular, it has been shown that RARα and ERα
can bind overlapping DNA sequences and cooperate or antagonize to regulate gene expres-
sion74;75. Such interactions may occur also to regulate SHOX expression. I performed in
silico analysis on the SHOX locus to identify potential binding sites for ERs and identified
different sequences in the SHOX promoter and intronic regions. Interestingly, some of these
sites overlapped with RARs and RXRs binding sites. It would therefore be interesting to
test whether estrogens regulate SHOX expression, whether there is interactions between es-
trogens and retinoids, and what the nature of such interactions is. Such data could help
elucidating the molecular mechanisms underlying the clinical manifestations variability ob-
served in SHOX deficiency male and female patients thereby broadening the understanding
of the intricate network regulating SHOX expression during bone development.
SHOX dosage plays an important role on individual height
Height depends mostly on the longitudinal growth of the limbs. Longitudinal growth of bones
occurs at the epiphysial plates or growth plates. Each growth plate is characterized by three
zones: the resting zone populated by round resting chondrocytes; the proliferating zone con-
sisting of flattened proliferating chondrocytes which organize in columns in the direction of
longitudinal growth; hypertrophic zone, composed of chondrocytes which undergo through
terminal differentiation by withdrawing from the cell cycle and increasing their volumes. The
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volume increase of hypertrophic chondrocytes contributes to long bone lengthening. These
processes are tightly regulated and are orchestrated by a complex network of factors and
genes; SHOX is a key player among them. Single nucleotide variants and deletions in SHOX
gene and enhancers have been shown to lead to variable short stature phenotypes. Interest-
ingly, gene dosage of SHOX has been shown to determine height: SHOX deficiency causes
short stature, whereas SHOX overdosage has been associated to tall stature in Klinefelter
individuals or 47,XXX females25. SHOX has been suggested to repress growth plate fusion
and skeletal maturation in the distal limbs. SHOX deficiency is characterized by premature
epyphyseal plate fusion and relatively advanced skeletal maturation. In Klinefelter patients,
for example, a SHOX overdosage leads to a delayed growth plate fusion and consequently to
longer limbs25. Thus, different dosages of the SHOX protein play an important role in deter-
mining the height of an individual. We have found that damaging mutations in CYP26C1 in-
creases RA levels, which reduces SHOX dosage and exacerbate SHOX deficiency phenotypes.
To corroborate this hypothesis, we titrated the amount of each MOs down to a concentration
not sufficient to trigger a phenotype. We have demonstrated that the co-injection of these
subphenotypic dosages of shox and cyp26c1 MOs strongly shortened pectoral fins (Figure
3.17).
CYP26C1, not only a modifier for SHOX deficiency
In our zebrafish model of cyp26c1 MO knockdown pectoral fins were affected. Embryos
showed also abnormalities of otic vesicles and pharyngeal arches (Figure 3.12).
Homozygous/compound heterozygous damaging variants in CYP26C1 have been previ-
ously associated with focal facial dysplasia type IV (FFDD4), a mild disorder of the skin
characterized by bitemporal or preauricular vesicular skin lesions76. In this study, only the
skin lesions were described; other abnormalities were not reported and height and skeleton
were not analysed. Interestingly, zebrafish otic vesicles and pharyngeal arches are structures
that encompass the sites of the skin lesions observed in FFDD4 patients. Thus, the cyp26c1
zebrafish MO knockdown may represent a model for the analysis of both LWD and FFDD4.
CYP26C1 heterozygous individuals were reported as not affected in the FFDD4 study. In
SHOX deficiency patients with CYP26C1 heterozygous damaging variants as reported in this
thesis, skin lesions were not diagnosed. Moreover, we also report an individual (Family 3, the
father) carrying a damaging variant in CYP26C1 who did neither show an obvious skeletal
nor FFDD4 phenotype. It is therefore possible that, in contrast to our zebrafish model,
deficiency of CYP26C1 alone does not lead to obvious short stature and/or dysmorphic
phenotypes nor FFDD4.
As mentioned in the Introduction, CYP26A1, B1 and C1 are all members of the cytochrome
P450 26s subfamily of enzymes. All three genes are able to catabolize RA8 and are present
in human, mice, and zebrafish. Uehara et al. have shown that loss of Cyp26a1 in mice leads
to hindbrain defects. Cyp26a1 knockout mice brain phenotypes are, however, milder when
compared to RA treated animals. Loss of Cyp26c1 does not affect embryonic development
and mice are viable and fertile72, suggesting functional redundancy among Cyp26s genes.
Interestingly, loss of both Cyp26a1 and Cyp26c1 leads to severe brain abnormalities during
development when compared to single knockout and these phenotypes resemble those induced
by RA treatment. These data suggest that Cyp26a1 and Cyp26c1 play redundant roles in
the control of RA levels. Similar data have been shown in zebrafish embryos hindbrain devel-
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opment77 and likewise, Kinkel et al. reported functional redundancy among the three cyp26s
genes in the regulation of the pancreatic field in zebrafish embryos78. It is therefore possible
that damaging mutations in CYP26C1 are compensated by CYP26A1 and/or CYP26B1 to
prevent the cells to be exposed to excessive RA levels, protecting from FFDD4 and skeletal
phenotypes in the context of a SHOX wildtype genotype. However, CYP26C1 heterozygous
damaging variants can still lead to RA amounts high enough to downregulate SHOX expres-
sion and to up- or down-regulate other genes in the limbs, modifying towards more severe
SHOX deficiency phenotypes.
To address the question whether CYP26C1 damaging variants alone can play a role in
short stature, we analyzed the coding sequence of this gene in 256 individuals with ISS and
LWD where SHOX deficiency could be excluded. The present data do not provide support
for a role of CYP26C1 alone in the aetiology of short stature (Figure 3.5). On the other
hand, this hypothesis cannot be excluded without a systematic analysis, as it may lead to less
dramatic effects compared to SHOX deficiency. Screening of a larger cohort of short stature
individuals with detailed clinical data could answer this question. Based on the present data,
we postulate that certain CYP26C1 variants do not have detectable effects in the absence of
SHOX deficiency but are capable of modifying the phenotypic outcome of SHOX deficiency
towards higher penetrance and stronger severity. Accordingly to this hypothesis, Grüneberg
defined modifier genes as "capable of modifying the manifestation of a mutant gene without
having an obvious effect on the normal condition"79.
Conclusions
The aim of my thesis was to elucidate the genetic causes of clinical variability observed in
patients with SHOX deficiency. Only a few genetic modifiers have been reported in the litera-
ture so far80–85, but recent technological advances are helping to broaden the understanding
of the molecular basis of quantitative or discrete qualitative differences in phenotype. A
primary reason to identify disease modifiers is to enable the accurate prediction of disease
progression and improve therapeutic development. We uncovered one of the component of the
RA pathway, CYP26C1, as biological modifier of the penetrance and expressivity of SHOX
deficiency. Based on the reported data we propose the following model: In individuals with
normal height, SHOX wild type regulates the transcription of its target genes to accomplish
endochondral ossification. CYP26C1 controls that the RA intracellular levels do not exceed
a determined concentration leading to normal growth and development (Figure 4.1a). In
individuals with heterozygous mutations or deletions of SHOX gene, the complex and del-
icate network of factors and genes is dramatically affected, leading to LWD. However, the
penetrance of SHOX deficiency is not complete and some individuals present with stature
within the normal range and no dysmorphic phenotype. Damaging variants in CYP26C1
affect its catabolic activity leading to high levels of RA which alter the gene expression pro-
gram regulating endochondral ossification. SHOX is among the genes which are disregulated
by higher levels of RA. Hence, the combination of SHOX and CYP26C1 deficiencies alter
chondrocytes differentiation and hypertrophy at the growth plates of long bones resulting in
shortened mesomelic limbs and Madelung deformity (Figure 4.1b). We propose that ma-
nipulating the RA signalling pathway in these patients may be therapeutically beneficial.
Finally, I would like to conclude by addressing an important point which needs to be clar-
ified by further studies. Why do some individuals bearing SHOX damaging variants (Family
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1, individuals III:3, III:5 and III:6; Family 2, individuals I:1 and II:1) not present with LWD?
In family 1, individuals III:4 and the twins III:5 and III:6 do not share the same parents.
Therefore, it is unlikely that they bear common genetic factors that protect them from SHOX
deficiency. The SHOX variant identified in Family 2, p.L132V, has already been reported
in another independent family suggesting that it can lead to LWD (although it would be
interesting to analyze CYP26C1 in this family). Moreover, functional analyses of the SHOX
variants identified in family 1 and 2 show a strong damaging effect on protein activity, further
corroborating causality. Not only missense mutations but also deletions of SHOX exome or
its regulatory regions have been reported in normal stature individuals without dysmorphic
signs19;47;48. Hence, I hypothesize that the genetic background has a stronger effect than
SHOX allelic variability in the clinical variability observed in SHOX deficiency individuals.
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Figure 4.1: Schematic representation of CYP26C1 modifier effect on SHOX deficiency.
(a) Individuals with SHOX and CYP26C1 wildtype. CYP26C1 regulates RA levels within the phys-
iologic concentration range. The complex network of factors and genes involved in endochondral
ossification remains unaffected leading to a normal phenotype. Normal height can also be observed
in some cases of SHOX deficiency since penetrance is not 100%. Individuals carrying CYP26C1
damaging variants show normal height. (b) Individual carrying damaging mutations in SHOX and
CYP26C1. Damaging mutations in CYP26C1 affect its catabolic activity leading to higher intracel-
lular levels of RA. Excess of RA dysregulates its target genes expression; SHOX is downregulated.
In case of SHOX deficiency, further decrease of its protein affects the complex network regulating
bone formation leading to delayed ossification. These cellular/molecular mechanisms exacerbate
the penetrance and severity of LWD.
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Appendix Figure 1: Schematic representation of genome-wide LOD score calculations.
LOD scores calculated with ALLEGRO are given along the y-axis relative to genomic position cM
(centi Morgan) on the x-axis. Note the highest peak (LOD score 2.4) in the region on chromosome
10 and a second lower peak in the XY PAR1 (LOD score 1.7). This analysis was performed by Dr.
Gudrun Nuernberg.
91
Appendix
Appendix Figure 2: Chromosome 10 region identified by whole-genome linkage anal-
ysis. Pedigree of the family with associated SNPs co-segregating with the disease phenotype on
chromosome 10 is represented. A total LOD score of 2.4 was identified between the flanking mark-
ers rs10509480 and rs10509758 and covering a 19.2 Mb region (chr10: 85477515-104681710; hg19).
Filled symbol, LWD affected individual; symbol with a slash, deceased individual; slash, divorced;
arrow, index patient. Colored chromosomal regions show traceable inheritance; red color regions,
common haplotype co-segregating with LWD; black lines, regions affected by a crossing over of
unknown location.This analysis was performed by Dr. Gudrun Nuernberg.
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Appendix Figure 3: Chromosome X, PAR1 region identified by whole-genome linkage
analysis. Pedigree of the family with associated SNPs in the pseudo-autosomal region 1 (PAR1) of
chromosome X is represented. A total LOD score of 1.7 was identified between the flanking markers
rs3995646 and rs5939344 and covering a 2.02 Mb sequence (chrX: 706800-2735491; hg19). Filled
symbol, LWD affected individual; symbol with a slash, deceased individual; slash, divorced; arrow,
index patient. Colored chromosomal regions show traceable inheritance: red color regions, common
haplotype co-segregating with LWD; black lines, regions affected by a crossing over of unknown
location.This analysis was performed by Dr. Gudrun Nuernberg.
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Appendix Table 1: Variants identified by whole exome sequencing of individuals II:3
and III:2 in Family 1. *, variants analysed by Sanger sequencing.
Gene symbol Position (hg19) Annotation Reference allele Altered allele Protein change
MYOM3 chr1:24411024-24411024 missense C T Gly>Ser
MACF1* chr1:39853900-39853900 missense G A Arg>Gln
DMAP1 chr1:44680270-44680270 missense A G His>Arg
IGSF3* chr1:117120054-117120054 missense G C Ser>Arg
PRRC2C chr1:171501788-171501788 missense C T Leu>Phe
LAX1 chr1:203740509-203740509 missense C T Leu>Phe
CR1L chr1:207871016-207871016 missense G C Arg>Thr
EXO1* chr1:242023901-242023901 missense A G Asn>Ser
PLB1* chr2:28843766-28843766 missense C G Pro>Ala
SFXN5 chr2:73198732-73198732 missense G T Asn>Lys
IFIH1 chr2:163137930-163137930 missense C T Val>Met
UNC80 chr2:210680059-210680059 missense C T Arg>Cys
TRNT1 chr3:3170866-3170866 missense C A Leu>Met
CX3CR1 chr3:39307125-39307125 missense G C Ile>Met
ZNF501 chr3:44776352-44776352 missense A G Ile>Val
KIF15 chr3:44842943-44842943 missense C A Asp>Glu
KIF15 chr3:44842940-44842940 missense A G Asn>Asp
DALRD3 chr3:49053308-49053308 missense A G Leu>Pro
USP19* chr3:49150049-49150049 missense C T Arg>His
KIAA1407 chr3:113755502-113755502 missense T C Lys>Glu
LRRC31 chr3:169558026-169558026 missense T C Ala>Val
LSG1 chr3:194362876-194362876 missense G A Ala>Val
FAM53A chr4:1643268-1643268 missense G A Val>Leu
HTT chr4:3138013-3138013 missense C G Asp>Asn
RCHY1 chr4:76434139-76434139 missense G T Gln>Lys
HNRNPD chr4:83277824-83277824 missense T C Asn>Ser
LARP7* chr4:113574284-113574284 missense G A Asp>Asn
C4orf43 chr4:164436515-164436515 missense G A Ser>Asn
NKD2 chr5:1038357-1038359 indel GAG delGAG delGlu
AGXT2 chr5:35026520-35026520 missense T C Ile>Val
SPEF2 chr5:35654784-35654784 missense C T Arg>Trp
IQGAP2 chr5:75886262-75886262 missense G A Ala>Thr
ECSCR chr5:138837381-138837381 missense C T Gly>Ser
FAT2* chr5:150885332-150885332 missense G A Arg>Trp
ADAM19* chr5:156915281-156915281 missense C T Val>Ile
TRIM7 chr5:180622230-180622230 missense T C Gln>Arg
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PKHD1 chr6:51915066-51915066 missense C A Arg>Leu
LRRC1 chr6:53767447-53767447 missense A G Ile>Val
CHCHD2 chr7:56172142-56172142 missense G T Pro>His
HIP1 chr7:75184840-75184840 missense G A Leu>Phe
PCLO* chr7:82764707-82764707 missense G A Ala>Val
OR2A12 chr7:143792647-143792647 missense A G Ile>Met
BLK chr8:11418747-11418747 missense G T Gln>His
FDFT1 chr8:11683560-11683560 missense G A Gly>Arg
PIP5K1B* chr9:71509400-71509400 missense G C Gly>Ala
NDOR1 chr9:140110737-140110737 missense A G Met>Val
ZNF33B* chr10:43088356-43088356 missense A G Ile>Thr
SUPV3L1* chr10:70968696-70968696 missense A G Met>Val
OPN4* chr10:88419701-88419701 nonsense C T Gln>Stop
CYP26C1* chr10:94828408-94828408 missense T G Phe>Cys
SUFU* chr10:10463959-10463959 missense C T Ala>Val
NRAP* chr10:115401182-115401182 missense C T Gly>Glu
DOCK1* chr10:1292311563-1292311563 missense A T Asp>Val
OR51G1 chr11:4944650-:4944650 missense T C Lys>Arg
PDE3B chr11:14853242-14853242 missense A G Ile>Met
DCDC1 chr11:31159274-31159274 missense T C Met>Val
TNKS1BP1* chr11:57087776-57087776 missense C T Glu>Lys
ZDHHC5 chr11:57456934-57456934 missense T C Val>Ala
OR1S2* chr11:57971241-57971241 missense G A Ala>Val
VWCE chr11:61026257-61026257 missense C T Val>Met
SLC22A25 chr11:62932035-62932035 missense T C Thr>Ala
USP28* chr11:113683078-113683078 missense C A Arg>Ile
GPD1* chr12:50500117-50500117 missense T C Ile>Thr
RIMBP2* chr12:130926846-130926846 missense C T Val>Ile
PCDH8* chr13:53421007-53421007 missense C T Arg>His
SLC10A2* chr13:103701773-103701773 missense G A Thr>Met
LIG4* chr13:108861778-108861778 missense T G Lys>Asn
NRXN3 chr14:79181204-79181204 missense G A Arg>His
TJP1 chr15:30010841-30010841 missense C A Gly>Cys
OAZ2 chr15:64980961-64980961 missense C T Arg>Gln
ACAN* chr15:89395216-89395216 missense A T Thr>Ser
FLYWCH1* chr16:2983445-2983445 missense A T Ser>Cys
ABAT chr16:8868826-8868826 missense G A Gly>Asp
TXNDC11* chr16:11791994-11791994 missense G A Pro>Leu
ZNF267* chr16:31927549-31927549 missense A G Tyr>Cys
CHD3 chr17:7814208-7814208 missense C T Ala>Val
PIK3R6* chr17:8796223-8796223 missense G A Ala>Val
95
Appendix
AOC2* chr17:40997824-40997824 missense G A Arg>Gln
ANKRD40 chr17:48784984-48784984 missense T A Gln>Leu
CLTC* chr17:57760484-57760484 missense C T Thr>Ile
TMC6 chr17:76120993-76120993 missense G A Arg>Trp
TMC8 chr17:76135150-76135150 missense G A Arg>His
LAMA1* chr18:6950948-6950948 missense G A Arg>Cys
DOHH chr19:3492394-3492394 missense G A Pro>Leu
ZNF266 chr19:9524511-9524511 missense T A Asn>Tyr
ANKRD27 chr19:33110404-33110404 missense G A Ser>Phe
FTL chr19:49469240-49469240 missense A G Arg>Gly
NAT14 chr19:55998176-55998176 missense G T Met>Ile
CST5 chr20:23860141-23860141 missense A C Val>Gly
SYNDIG1* chr20:24646111-24646111 missense G A Ala>Thr
TUBB1 chr20:57598870-57598870 missense C G Leu>Val
BIRC7* chr20:61867717-61867717 missense G A Arg>His
IFNAR2 chr21:34621124-34621124 missense G A Val>Ile
AP1B1 chr22:29750745-29750745 missense C T Gly>Ser
SLC5A1 chr22:32479136-32479136 missense G T Gly>Val
TRMU chr22:46752825-46752825 missense C G Pro>Ala
DMD chrX:31284928-31284928 missense C T Gly>Ser
KIF4A* chrX:69510287-69510287 missense AG AC -
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Appendix Table 2: Variants identified in Family 1 and by screening the coding regions
of CYP26C1 in 68 individuals with LWD and SHOX deficiency.
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Appendix
Appendix Table 3: Variants identified by screening of CYP26C1 in 140 healthy control
individuals.
Transcript
c.639C>T c.705+4C>T c.734G>A c.1191+69_1191
+ 75delCTGCCGC
Protein p.Thr213= p.- p.Arg245Gln p.-
Annotation synonymous splice region missense intron
rsID rs55843714 rs58993699 rs11187265 rs76924069
Mutation
polymorphism polymorphism polymorphism polymorphism
taster
Polyphen2 unknown unknown benign unknown
Provean neutral neutral neutral unknown
SIFT tolerated tolerated tolerated unknown
Allele frequency
0.4857 0.0035 0.1178 0.2464
our cohort (136/280) (1/280) (33/280) (69/280)
Allele frequency
0.4687 0.01679 0.09819 not found
ExAC (53306/113722) (1790/106604) (11798/120154)
Allele frequency
0.2823 0.033 0.074 not found
TGP (1414/3594) (165/4843) (370/4638) ()
Allele frequency
0.4401 0.0289 0.085 not found
EVS (5673/7217) (352/11796) (106/11900)
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Appendix
Appendix Table 4: Variants identified in Family 1 and by screening the coding regions
of CYP26C1 in 68 individuals with LWD and SHOX deficiency.
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